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Abstract

THE ROLE OF MICRORNA-155 AND MICRORNA-146A AS PUTATIVE
ONCOMIRS IN THE TUMOR PROGRESSION OF PROSTATE CANCER
By Jennifer Renee Hoyt, M.S.
A thesis submitted in partial fulfillment of the requirements for the degree of Master of
Science at Virginia Commonwealth University School of Medicine.

Virginia Commonwealth University, 2008

Major Director: Zendra E. Zehner
Professor, Biochemistry

Prostate cancer is the most common cancer occurring in males. The identification
of novel microRNAs (miRs) that contribute to tumor progression represents prospective
treatment targets. miRs are small non-coding RNAs important in gene regulation with
specific tissue expression patterns. Each miR is thought to affect the expression of
hundreds of different RNA targets. Two putative oncomiRs, miR-155 and miR-146a,
were shown to be differentially expressed in the human derived, prostate cell sublines
M12 and F6. Quantification of endogenous miR expression showed high levels in the
metastatic M12 cell line versus low in its weakly tumorigenic F6 variant. The restoration
x

xi
of miR expression to M12 levels was evaluated on F6 growth, morphology, and in vitro
behavior. F6 plus miR-155 or miR-146a displayed increased growth, motility and
invasiveness when compared to M12, with less organized structural morphology when
grown embedded in matrigel. Altogether these results suggest that the overexpression of
miRs 155 and 146a could contribute to tumor progression in vivo.

INTRODUCTION
Prostate Function and Structure
The prostate is an accessory reproductive organ within the male urogenital system
composed of many acini that lead into ductules, which together function to create an
exocrine gland. The male urethra is completely encircled by the prostate and serves as a
receptacle repository for prostate epithelial secretions, such as prostate specific antigen
(PSA), spermine, proteases, and others. Although the prostate gland is secretory, only a
small portion of the gland has exocrine capabilities. The major cell types that form the
prostate gland are found within the highly proliferative epithelium. The epithelium is
known to contribute to the medical pathologies of benign prostate hypertrophy (BPH),
proliferative inflammatory atrophy (PIA), prostatic intraepithelial neoplasm (PIN), and
prostate carcinoma (PCa) (1). The prostate epithelium is composed of a layer of luminal
cells and a layer of basal cells immersed within mesenchymal stromal cells (1-3). These
two epithelial cells have distinct functions, localization, and morphological differences
(4). The luminal cells are tall columnar cells that line the ductal lumen (1, 2), produce
exocrine secretions such as PSA and prostatic acid phosphatase (PAP), express androgen
receptor and keratins (K) 8 and 18, and are differentiated with a high apoptotic index (3,
5). Basal cells are stretched cubiodal cells found juxtaposed between the luminal cells
and the basement membrane (2), are further characterized by the expression of K5, 14,
1

2
and 18, an absence of PSA, PAP, androgen receptor, and are undifferentiated with a high
proliferative capacity (3, 5). Neuroendocrine cells can be found dispersed throughout the
prostate epithelium releasing paracrine secretions of neuropeptides and hormones to
potentially modulate proliferation and differentiation of exocrine cells (2, 5).
The developing prostate is marked by an androgen dependent mesenchymal-stromal
maturation, which contributes to the differentiation and development of the epithelium.
The secretion of androgen by stromal cells allows subpopulations of cells containing
androgen receptor to further differentiate into luminal cells. The prostate is considered an
androgen dependent organ, but contains a heterogeneous mixture of undifferentiated
epithelial cells that do not express androgen receptors (i.e. basal) and differentiated
epithelial cells (i.e. luminal) and the mesenchyme that do express high levels of androgen
receptor. All cells within the epithelium begin androgen receptor negative until
differentiation allows the expression of androgen receptor in luminal cells. In addition to
the normal androgen receptor expression during maturation, the androgen receptor has
been found to have a higher and more heterogeneous expression throughout the luminal
and stromal cells during prostate hypertrophy and malignancy states (1).

The

mesenchymal stromal cells also influence the development of the prostate epithelium
through the secretion of various factors (2, 6), such as epidermal growth factor (EGF),
transforming growth factor-α (TGF-α), insulin growth factors (IGF), and fibroblast
growth factor (FGF) (2). These factors interact in a paracrine fashion with epithelial cells
leading to glandular and ductal development and continued proliferation (2, 5). In return,
the differentiated epithelium acts in a cell-to-cell manner with mesenchymal smooth
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muscle cells inducing their differentiation and morphological sheet structure. Therefore,
the overall development of the prostate is due to the androgen dependent mesenchyme
interacting with the semi-androgen and growth factor-dependent epithelium in a paracrine
loop.
The differentiation of cells within the epithelium has led to the discovery of two
additional cell populations, the intermediate transitional cells, based on keratin express.
As previously noted, basal cells expression high levels of K5, K14, and moderate levels
of K18 and luminal cells express high levels of K8 and K18. The first intermediate
transitional cell is the intermediate basal cell expressing high levels of K5 and K18, no
K14, and resides within the basal epithelial compartment juxtaposed to the luminal cells.
The second intermediate transitional cell is the intermediate luminal cell expressing
moderate levels of K5, high levels of K18, and resides juxtaposed to basal compartment
(2, 4). In addition, there has been positive antibody labeling of the neuroendocrine cells
showing a presence of K5 and K14, indicating both luminal exocrine and neuroendocrine
cells are potentially derived from the same intermediate cell lineage (2, 5).
The origin of the prostate epithelium has been postulated to originate from a stem cell
that behaves like other epithelial stem cells (i.e. intestinal) and undergo asymmetrical
division to create an undifferentiated stem cell and a differentiated progenitor cell (2, 4,
5).

Due to the high proliferative capacity and undifferentiation of basal cells, along with

an overabundance of their intermediate cells during neonatal, perinatal, and postnatal
development (5), it is believed that the prostate epithelium stem cells are found within the
basal cell compartment (2, 4), although there have been no direct markers for this
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putative stem cell (3). Thus, it has been theorized that the prostate itself begins with a
basal stem cell that proliferates and differentiates through intermediate cell lineages to
create basal cells and differentiated exocrine luminal cells and neuroendocrine cells, in
the presence of mesenchymal-stromal influences (2, 4, 5).
The prostate gland contains three distinct histological glandular zones: the transitional
(5%-10%, bilateral to the urethra), central (20%-25%, surrounding the ejaculatory ducts),
and the peripheral (70%-75%, lateral aspects of the gland). The transitional zone,
although composing the smallest amount of the gland, is unique in its likelihood for
continued growth throughout life, the process seen with BPH. The central zone has
larger acini, more complex ductal branching and sac-like formations, and dense stroma,
whereas the peripheral zone has smaller acini, less complex ductal branching, and loose
stroma. The peripheral zone accounts for most prostatic carcinomas and inflammation,
whereas the central zone is only responsible for approximately 5% of carcinomas (1).

Pathology of Prostate Carcinoma
Prostate cancer is the top diagnosed cancer in males within the United States, with the
second highest mortality rate, the first being lung cancer. An estimated 186,320 new
cases and 28,660 deaths are expected in 2008, fortunately down from 232,090 estimated
cases and 28,905 deaths in 2005 (7). Being the leading cancer in the male population, the
pathology of prostate carcinoma has become increasingly important, serving as potential
targets for therapeutic agents. The pathology has been hard to define due to a complexity
of multiple integrating pathways that could potentially lead to the progression of prostate
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tumors, although gene mutations, amplifications, deletions, and chromosomal
rearrangements seem to be the basis for carcinoma. It is uncertain if the androgen
receptor serves a concrete role in prostate carcinoma development, but its quantification
has shown an up regulation in the nucleus in BPH, PIN, and prostate cancer compared to
normal prostate tissue levels. There is an increasing heterogeneous localization of
androgen receptor in the nucleus and cytoplasm in prostate cancer (1). Most first line
prostate cancer therapeutic agents are androgen suppressors that deplete androgendependent cells through apoptosis, but inevitably select for and promote the emergence of
androgen-independent prostate cancer cells (8). Some of these androgen-independent
cancer cell lines, PC3 and DU145, have continuous high androgen receptor expression
for androgen receptor mediated cell growth (1).
There are many characterized mutations of tumor suppressor and oncogenic proteins
that affect the metastatic nature of prostate cancer, such as an over-expression of the Ras
family and Myc oncogenes or mutations in tumor suppressors, such as PTEN, p53, and
Rb that lead to increased proliferation and decreased apoptosis. Prostate cancer is also
hallmarked by mutations resulting in the loss of specific adhesion factors or keratin
patterns. One of the most notable losses is E-cadherin, which allows for cell-to-cell
adhesion. Its loss is found in over 50% of prostate tumors, pointing to its importance in
tumor progression. In addition to losses, a normal prostate epithelial cell may undergo
stressors, such as phagocytic inflammatory cell damage, oxidative stress, or DNA
damage, which expands the intermediate epithelial cell line and leads to the proliferative
inflammatory atrophic (PIA) cell. Further accumulations of somatic gene alterations
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push the atrophic cells into PIN, and with even more accumulations of genomic changes
(gain of oncogenes or loss of tumor suppressors) the original altered cells become an
invasive carcinoma (1). Therefore, proliferative inflammatory atrophic sites within the
prostate are believed to serve as a jumping stone into proliferative atrophy neoplasm and
prostate cancer and reflect focal lesions that are associated with chronic prostatic
inflammation (8). These atrophic areas are characterized by proliferative atrophic
appearing epithelial cells that fail to differentiate into luminal secretory cells and are
localized to the periphery of the prostate near inflammatory cells, where most cancers are
suspected to arise (1, 8).
There are multiple and highly accessible screening tools for this disease. Digital
rectal exams (DRE) are manually performed by a licensed medical professional who
palpates the prostate per rectum. The DRE allows for the diagnoses of BPH and earlystage prostate cancer that is still localized to the primary site. A second screen tool is the
PSA test, which is an organ specific test that quantifies the amount of PSA leaked into
stromal cells that then enters the blood stream and is metabolized in the liver. A third
tool is the Gleason grade, which serves as a marker to measure the extent of malignant
prostatic tissue. The Gleason system is based solely on the architectural pattern of cells
within the prostate gland, with scores ranging from 1 to 10. Gleason scores of 1 and 2
represent a tumor consisting of closely packed uniform, single, and separate glands,
representing well differentiated cells. Gleason score of 2 through 4 also represent well
differentiated cells; Gleason score of 5 to 6 represent moderately differentiated cells;
Gleason score 7 are moderately poorly differentiated cells; and Gleason score of 8
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through 10 is poorly differentiated cells (characteristic of invasive and aggressive tumors)
(1).

Prostate Epidemiology
As previously noted, prostate cancer is the leading cancer diagnosed in males with the
second highest mortality rate (7). Genetics, diet, lifestyle, age, and familial history of
prostate cancer all can potentially contribute to the development and progression of
prostate malignancy (1, 8). Age is one of the most important indicators for prostate
cancer. The distribution of incidence cases ranges from 35 through 85+ years of age,
with 86.1% of those cases seen between ages 55 and 84 and 68 years old being the most
common age of diagnosis. The highest percentage of deaths due to prostate cancer is
after the age of 75, with a median age of 80. Males have a 15.78% (1 in 6) lifetime risk
of being diagnosed with prostate cancer and a 2.83% lifetime risk of dying from prostate
cancer; black males have an 18.25% lifetime diagnosis and 4.43% lifetime death risk, and
white males a 15.25% and 2.65% risk. It is shown that Asian men have low incidence
rates, northern European countries having a higher incidence, but the highest always
occurs in African American men (9).
Some dietary risks have been contraindicated in prostate cancer (1, 8, 9). An increase
consumption of animal and saturated fats, red meat, dairy products, and calcium has been
indicated in increasing the risk of prostate cancer (8), via increases in cell proliferation
and angiogenesis and decreases in cell differentiation and apoptosis (1). Vitamin E and
selenium have been shown to decrease the risks (1, 8, 9). It has been postulated that diets
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in different geographical locations may contribute to the incidence variation between
populations. For example, in the 1980’s Asian males that consumed more soy products
containing phytoestrogens had a 1 in 100,000 incidence rate of prostate cancer, whereas
African American males had an incidence rate of 82 in 100,000. Some lifestyle habits,
such as tobacco smoking or alcohol consumption, have also been postulated to modulate
prostate cancer risks, but have no definitive correlation (1, 9).
It is proposed that acute and chronic alcohol consumption leads to the decrease of
circulating testosterone, which in return is unable to act on the prostate in an androgen
dependent manner, potentially altering the risk of prostate cancer. However, inconclusive
case studies have been reported. Tobacco smoking does have a positive correlation to
lung cancer, but has no direct correlation to prostate cancer development. Although, it
has been shown that tobacco smokers have a higher prostate cancer mortality risk,
potentially due to the carcinogens in tobacco that promote tumorigenesis and gene
mutation (1). Other lifestyle habits or choices, such as men that have undergone
vasectomies (9), certain occupations, and even non-steroidal anti-inflammatory drug
consumption, have shown conflicting results in the modulation of prostate cancer (1).
The most controllable prostate cancer risks reside with diet and lifestyle changes, but
the uncontrollable sequential genetic alterations within the prostate can promote cancer
progression. Many somatic loss of heterogeneity changes occur in prostate tumor
progression, especially the partial or total loss of chromosomes. Such examples can be
found on chromosome 8p, 10q, 16q, 19p, and 19q, with the loss of 19p and 19q
chromosome arms seen more often in end-fatal prostate cancers. Tumor progression by
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loss of chromosome segments can be reversed by chromosomal transfer, in which some
regions of transferred chromosomes suppress cell metastases, such as chromosome 8 and
11 (1). Many genes have been identified and hallmarked in organ-specific cancers, such
as BRCA1 and 2 in breast cancer. The identification of prostate-specific gene markers
has been evaluated through genetic mutations and alterations in families with prostate
cancer clusters (1, 9). It is believed that 5% to 10% of prostate cancer is primarily due to
inherited susceptibility genes (8) or more specifically hereditary prostate cancer genes
(1). Family and twin studies have concluded the risk of a male being diagnosed with
prostate cancer increases if a brother or father had prostate cancer, producing a two to
three-fold increase in the risk (9). Other studies have resulted in a link between breast
cancer and prostate cancer, showing an increase in prostate cancer risk in men with a
family history of breast cancer in his mother and/or sister(s) (1, 9).

Prostate Cancer Cell Lines
Determining the parameters that control the metastatic nature of prostate cancer and
the events during cancer progression define the importance of developing and
investigating cancer cell lines. In order to investigate the variances between nonmetastatic and metastatic tumor cells, the most recognized prostate cancer cell lines have
been used, PC-3, DU-145, and LNCaP (10). Although these three prostate tumor cell
lines are widely used, they share no genetic background and were all derived from
metastatic sites, not the primary prostate tumor, raising concern to their aneuploid
karotype. The development of a genetically related prostate carcinoma cell line came
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about through the immortalization of prostate epithelial cells, P69, directly from the
prostate gland. Through in vivo injections into athymic nude mice the formation of a
metastatic cell line, M12, arose. The P69 parental prostate cell line and its sublines
provide an opportunity to study the genetic variances between metastatic-tumorigenic
cells versus non-metastatic and barely tumorigenic cells and what potentially allows for
the emergence of metastatic phenotype during human prostate epithelial tumor
development (11).
The DU-145 cell line was obtained in 1975 from a 69-year-old Caucasian male with
primary prostate carcinoma and multiple metastatic sites. The sample was collected from
one of the prostatic metastatic sites, a central nervous system lesion. These cells, which
possess K8 and K18, are tumorigenic in nude mice, have anchorage-independent growth,
and lack PSA. In addition, these cells are not responsive to hormones, nor are they
dependent. DU-145 produce high levels of EGF and TGR-α along with high levels of the
EGF-receptor, all of which act in an autocrine fashion to stimulate cell proliferation.
These cells also produce insulin-like growth factor-1 (IGF-1) and IGF-receptors, which
can be exogenously stimulated by IGF. TGF-β causes cell proliferation inhibition. An
up regulation of transferrin receptor has been noted. The up regulation and possible
amplification of some growth factor and growth factor receptors is believed to cause the
androgen de-sensitivity (10).
The PC-3 cell line is a poorly differentiated prostatic adenocarcinoma obtained from
the lumbar vertebra metastatic site of a 62-year-old Caucasian male with primary prostate
carcinoma. These cells possess K8 and K18, are believed to be absent of PSA, and are
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hormone unresponsive, although faint staining of PSA and nuclear androgen receptor
have been reported. PC-3 cells express high levels of TGF-α and EGF-R mRNA, which
may contribute to their autonomous growth or androgen independence. Up regulation of
transferrin receptor is also noted, with an increased growth of both PC-3 and DU-145
cells in the presence of bone marrow transferrin. PC-3 cells are inhibited by exogenous
TGF-β with initial exposure, but return to normal and express high affinity for TGF-β
receptors and secrete active TGF-β. These cells are also anchorage growth independent
(10).
LNCaP cells were derived from the metastatic site of the lymph node in a 50-year-old
Caucasian male diagnosed with moderately differentiated primary prostate carcinoma. It
is important to note that this patient was treated with estrogen and hormone therapies
without much success. These cells possess K8 and K18, like PC-3 and DU-145, and have
a low anchorage growth dependency. Unlike the PC-3 and DU-145 cells, LNCaP cells
have PSA, PAP, nuclear androgen receptor, and are androgen responsive for cell
proliferation control. LNCaP cells secrete EGF and TGF-α, and through androgen
binding to androgen receptors the EGF-R is up regulated, thus providing a growth model
of hormone and growth factor co-stimulation. TGF-β did not affect cell proliferation
(10). Chung et al. produced a human prostate cancer progression model from the LNCap
cells, beginning with the subcutaneous injection of LNCap and osteogenic sarcoma cells
into male athymic mice, later castrating them and harvesting the tumors, creating the first
subline LNCap-C4. Successive introduction of harvested tumors into nude mice created
multiple sublines beginning with androgen responsive LNCap-C4 cells and progressing
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to LNCap-C4-2 and LNCap-B4, which display increasing androgen independence,
invasiveness, and growth (12).
P69 cells were isolated from portions of a benign prostate gland from a 63-year-old
black male and immortalized with a SV40 large-T antigen gene construct. These cells
represent non-neoplastic epithelial cells without tumorigenic behavior or morphology.
After subcutaneous injection of P69 cells into 18 athymic nude mice, 2 mice
spontaneously developed tumors after a latency period of six months. Those two tumors
were isolated and through a series of in vitro passages and three in vivo passages a highly
metastatic and tumorigenic M12 subline was produced (10, 13). The M12 subline
produced tumors in all mice following intraprostate injection, showing extensive
metastatic distribution through the lungs, diaphragm, and often into the bladder, but
without obvious metastases to bone. The tumorigenicity and metastatic nature of the
M12 subline never declined through in vitro passages (15). Both the P69 cell line and
M12 subline also lack the androgen receptor and are androgen unresponsive (11). The
conversion of the parental cells into fully metastatic cells was accompanied by several
chromosomal alterations, including an unbalanced translocation between chromosomes
16 and 19, resulting in the loss of 19p and partial loss of 19q (14, 15). The breakpoint on
chromosome 16 is near a site most frequently deleted in human prostate adenocarcinomas
that have lost 16q, which includes genes E-cadherin and c-myc (15). The importance in
the loss of chromosome 19 in the M12 metastatic cells was investigated with the
restoration of a neomycin tagged human chromosome 19 via microcell-mediated
chromosome transfer (MMCT), creating a hybrid subline, F6. F6 is characterized by its
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reduction in tumorigenicity in vivo through subcutaneous and intraprostatic injections
into athymic nude mice and an increase in in vitro doubling time and anchor-dependent
growth (14, 15) (Figure 1). The F6 subline also shows a marked reduction in vimentin
mRNA and protein levels compared to M12, correlating to a decrease in tumorigenic and
metastatic behavior. In addition, M12 cell line shows a positive expression of K8, the
keratin found in basal cells (15).

MicroRNA Biological Function
Several layers of gene expression regulation occur within living organisms transcriptional, post-transcriptional (mRNA processing, transportation, and stability),
translational (protein production), and post-translational (protein stability). MicroRNAs
(miRNA) are small non-coding single stranded RNA molecules, only 21-22 nucleotides
in length, that function as post-transcriptional mRNA regulators through the specific
binding to complementary 3’ untranslated regions (UTR) of mRNA, causing a down
regulation of a specific message through degradation or translation repression (16). The
targeted message(s) control multiple biological processes, including developmental
timing, stem cell division, apoptosis, disease, and cancer (17). In the early 1990’s, miR
let-7 and lin-4 became the first discovered miRNA in the species Caenorhabditis elegans,
(C.elegans) (18), which was found to be involved in normal larval development.
Developmental disruptions occurred when these miRs were mutated (16). A comparison
of let-7 to the human genome found homologous sequences, suggesting miRNAs were
not specific to lower eukaryotes. miRNAs have been found in roundworm, plants, and
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Figure 1. Development of unique prostate cancer sublines from a non-neoplastic
prostate epithelial cell, P69. The P69 cell line was injected into 18 athymic nude mice,
with two forming spontaneous metastases. These metastatic tumors were retrieved,
passed in vitro, and then passed three times in vivo in athymic mice, obtaining the
metastatic and tumorigenic M12 cell line. An unbalanced translocation between
chromosome 16 and 19 was seen between P69 and M12, resulting in the loss of
chromosome 19. Reintroduction of chromosome 19 in the M12 cells produced the nonmetastatic and barely-tumorigenic F6 cell line.
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animals (16). As of October 2006, there were 474 known human sequences, with
estimates of over a thousand unknown miRNA sequences, potentially constituting ~3%
of the human genome. An estimated 10,000 genes or 30% of the human genome are
thought to be regulated by miRNAs (19). Most miRNA have been found in intergenic
regions and sometimes in clusters of several miRNAs. A few other human miRNA
genes are located within protein coding introns and occasionally exons (18), and also in
exons and introns of noncoding mRNA (20).
Several characterized miRNAs display essential functions during development, such
as miR-273 involved in C. elegans nervous system patterning. They can also function in
multiple unrelated mechanisms, such as miR-14 in Drosophilia melanogaster stressresponse pathway and fat metabolism regulation. In addition, many mammalian miRNAs
have been characterized in development: miR-181 in the differentiation of mammalian
haemopoietic cells towards B-cell development; miR-375 in mammalian pancreatic isletcell development and insulin secretion regulation; miR-143 during mammalian adipocyte
differentiation; miR-196 in mammalian limb patterning; and miR-1 genes during
mammalian heart development (21).

MicroRNA Biogenesis
Mammalian miRNAs go through multiple processing steps to yield the mature single
stranded post-transcriptional regulatory RNA. Processing starts with the synthesis and
transcription of the primary-miRNA (pri-miRNA) from DNA using RNA polymerase II
(16) (Figure 2). A transcript is created ranging in size from several hundred nucleotides
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Figure 2. MicroRNA biogenesis overview. The primary miRNA strand is transcribed
by RNA polymerase II, which is then cleaved by a microprocessor complex composed of
Drosha and DGCR8. The cleaved product is a pre-miRNA hairpin loop structure
containing the mature miRNA. The pre-miRNA is transported out of the nucleus via
Exportin-5 in a Ran-GTP manner, with release of the pre-miRNA in the cytoplasm upon
hydrolosis of GTP to GDP. Once in the cytoplasm, the pre-miRNA is recognized by
Dicer, which cleaves it to release a double-stranded miRNA complex. Dicer then
unwinds the double-stranded complex, releasing and guiding the mature miRNA strand
into the RISC complex (16).
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to several kilobases (22) and has a capped 5’ and poly-adenylated 3’ end (17). This primiRNA contains the mature miRNA sequence within a distinct stem-loop structure
(Figure 3). Next, a heterodimer microprocessor complex, consisting of two copies of the
double-stranded-RNA-binding protein DGCR8 and two copies of the RNase III
ribonuclease Drosha, initiates the binding and cleavage of the double stranded primiRNA (23). DGCR8 functions by directing Drosha in the specific processing of primiRNAs. Drosha cleaves the pri-miRNA at the base of the stem-loop, introducing a 2nucleotide 3’- overhang and 5’ phosphate at the cleaved site, resulting in the excision of a
~60 nucleotide precursor RNA strand, pre-miRNA (20). The pre-miRNA is transported
out of the nucleus into the cytoplasm in an exportin-mediated and Ran-GTPase manner
(24, 25). Exportin 5 is a karyopherin nucleocytoplasmic transport factor that requires
Ran-GTP to bind the double stranded pre-miRNA and facilitate nuclear export (24).
Exportin 5 is dependent on RNA structure, requiring at least 17-double stranded
nucleotides, but independent of sequence. Upon export into the cytoplasm, hydrolysis of
Ran-GTP to Ran-GDP induces the release of pre-miRNA from Exportin 5 (20).
The free cytoplasmic pre-miRNA is recognized by Dicer, another RNase III
ribonuclease, by high affinity for the 5’ phosphate and 2-nucleotide 3’ overhang (20) and
binds to the base of the stem-loop. Following binding, the ribonuclease symmetrically
cleaves the double stranded pre-miRNA stem-loop approximately two helix turns from
the first cleaved site, introducing the second 5’ phosphate and 2-nucleotide 3’ overhang
(26). This second cleavage process produces a ~22 nucleotide double stranded
miRNA:miRNA* duplex that remains associated with Dicer and is unraveled by an
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Figure 3. The structure of the pri-, pre-, and mature miRNA are located within a
distinct hairpin loop structure. The pri-miRNA is a long RNA transcript that upon
cleavage releases a shorter pre-miRNA with a 2 nucleotide 3’ overhang and a phosphate
attached to the 5’ end. Further cleavage of the pre-miRNA creates a double stranded
complex with two ends that both have 2 nucleotide 3’ overhangs and a phosphate
attached to the 5’ end (16).
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unknown RNA helicase (20). The mature miRNA, or guide strand, is one strand of the
duplex that is asymmetrically incorporated into the RNA induced silencing complex
(RISC) (17, 20). This asymmetric incorporation is due to RISC’s choice of the strand
whose 5’ end is less tightly paired (26) and is crucial for the stability and proper loading
into the RISC complex (21). The other strand, denoted miRNA*, gets degraded (18).
The mature miRNA guides RISC to mRNAs with a partially complementary sequence to
the miRNA (16).
miRNAs function through the 5’-end of miRNA base-pairing with RNA targets (27,
28), creating a down regulation of gene expression by either of two posttranscriptional
mechanisms: direct mRNA endonucleolytic cleavage or translational repression (17, 29).
A perfect complementarity of the miRNA to mRNA results in the cleavage of the mRNA
by RISC at nucleotide pairing position 10 and 11, with regard to miRNA target. If there
is less extensive complementarity between miRNA and RNA target, the mRNA will be
translationally repressed, potentially by de-capping or de-adenylating, resulting in mRNA
cleavage (29) (Figure 4). The miRNA 5’-end has been found to be evolutionarily
conserved, containing a “seed” region (nucleotides 2-8) that is thought to be responsible
for the specificity of base-pairing to the 3’ UTR of the target mRNA (21, 29). A
mutation in one nucleotide between 2 and 8 will cause loss of miRNA function, whereas
a mutation in either nucleotide 1, 9 or 10 does not alter expression. The extensive basepairing of the 5’-end of miRNA marks an important target site function, with a noted
importance in the nucleotide positions 2 through 8. There are three proposed basepairing mechanisms that allow miRNA to bind target mRNA - canonical miRNA:mRNA
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Figure 4. MicroRNAs function by repression of target mRNA. The RISC complex
with the mature miRNA target mRNA through mRNA cleavage and degradation (top
left) or mRNA translation repression (bottom right). mRNA cleavage is achieved when
the mature miRNA has perfect or near perfect binding to the 3’ UTR of the target mRNA.
mRNA translation repression occurs when imperfect matching occurs between the mature
miRNA and 3’ UTR of the target mRNA (16).
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interaction where both the 5’- and 3’-end of miRNA is used in binding, seed
miRNA:mRNA interaction that requires strong 5’-end of miRNA binding to mRNA and
little to no 3’-end pairing, and finally, 3’-compensatory interaction that needs a strong 3’end of miRNA binding to mRNA and weak 5’-end pairing. Although the 3’-end of
miRNA tends to be conserved, there has not been any role ascribed to the 3’-end (29).

MicroRNA Relation in Cancer
In healthy cells, the level of miRNAs and their targets are well balanced. A
disturbance of miRNA expression by either over expression or knock-out may contribute
to the initiation and maintenance of tumors (21, 30). The development of cancer is
dependent on interactions between oncogenes that promote cell proliferation and
tumorigenesis and tumor suppressor genes that repress cell division and tumor formation.
Cancer is described by five stages, initiation, promotion, malignant conversion (reduced
cell death and enhanced cell division), progression, and metastasis. A simplified view of
cancer is the amplification or over expression of oncogenes and suppression or deletion
of tumor suppressors (16).
Initial evidence showed a potential role for miRNAs in cancer with the
characterization of the 13q14 deletion in human chronic lymphocytic leukemia (CLL).
13q14 deletion has been seen in over half of the patients diagnosed with B cell-CLL (BCLL). It was observed that miR-15a and miR-16a were located within the deleted region
in B-CLL patients and approximately 68% of CLL patients had absent or down regulated
miR-15a and miR-16a levels. miR-15a and miR-16a negatively regulates BCL2 (an
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apoptotic protein), thus promoting cell proliferation (17). Following the initial evidence
in humans, many experimental mechanisms arose to evaluate the role of miRNAs in
cancer through profiling of miRNAs in both cancerous and normal tissues (16). Taqman
PCR has been used to evaluate precursor or active miRNA levels in tissue samples. The
most widely used analysis is the oligonucleotide miRNA microarray analysis, which
utilize high through-put analysis of known miRNAs in numerous malignant and normal
tissue samples to create a profile showing the distinct pattern of over expressed and down
regulated miRNA gene expression (31). A microarray screen by Gaur et al. (2007)
quantitated the level of 241 mature human miRNAs in 13 normal tissue samples and 59
tumor cell lines, showing a significant reduction of miRNA expression in cancer cell
lines (32). In addition, other microarray screen data has shown the following differential
tissue miRNA expressions: miR-221, miR-222, and miR-146 up regulated in thyroid
tumors; miR-143 and miR-145 reduced in colorectal neoplasia; miR-125b, miR-145,
miR-21, and miR-155 lower in breast cancer; miR-221 higher in gliobastoma multiforme
brain cancer and miR-181 lower in expression; let-7 down regulated in lung cancer
targeting Ras oncogenes; over expression of the miR-17-92 cluster in lung cancer
targeting PTEN and RB2 tumor suppressors (17, 31); and finally up regulated BIC gene
expression in Hodgkin and Burkitt lymphoma with the BIC gene encoding miR-155 (16).
Currently, the main mechanism that underlies changes in miRNA function in cancer
cells compared to corresponding normal tissues is aberrant gene expression, thus
resulting in abnormal levels of mature and/or precursor miRNA. The genetic
abnormalities that influence the activity of miRNA’s in cancer are the same abnormalities
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seen in protein-coding genes, such as chromosomal rearrangements, genomic
amplifications or deletions and mutations (31), providing further evidence of a role for
miRNAs in cancer pathogenesis (32). The proposed causes of abnormal miRNA
expression have been the location of miRNAs at cancer-associated genomic regions
(CAGRs), epigenetic regulation of miRNA expression, and abnormalities in miRNAprocessing genes and proteins (31, 33).
miRNAs are shown to be found in genomic regions that are prone to alteration in
cancer cells, including regions of loss of heterozygosity (LOH) near tumor-suppressor
genes and regions of amplications containing oncogenes (31). Fifty percent of annotated
human miRNAs are located in fragile break sites near putative tumor suppressors and/or
oncogenes associated in cancer (21). In addition, many miRNAs are found within
clusters on particular loci that have a high frequency of genomic alteration in human
cancers. For example, deletion of the locus containing miR-15a and miR-16-1 genes will
no longer allow for the repression of BCL2 resulting in a decrease in apoptosis (31).
Epigenetic changes, defined as mitotically and/or meiotically heritable changes in gene
expression that are not accompanied by changes in DNA sequence (30), are hallmarked
by DNA hypomethylation, CpG island hypermethylation, and histone-modification in
malignant transformations. For example, breast cancer cells with histone deacetylase
inhibition and histone deacetylase inhibitor PBA showed significant alterations in levels
of miRNA expression. Another potential cause for disruption in miRNA expression is an
alteration to any of machinery used during the biogenesis of miRNA, theoretically
causing dramatic effects in expression. The two most notable abnormal processes that
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have been noted occur in either Drosha or Dicer processing. Failure for Drosha to
process pre-miRNA from pri-miRNA results in the reduction of mature miRNA. As in a
fraction of lung cancers, a reduced level of Dicer can alter miRNA levels and has shown
correlation with a poor prognosis (31). In addition, an increase in Dicer has been seen in
prostate carcinoma along with a fourfold increase in expression of Dicer mRNA in the
Burkitt’s lymphoma derived cell line (34).
Despite the previous breakthroughs a role for miRNAs in cancer is still poorly
understood, but suggests miRNAs could be potential targets for therapeutics. Two
proposed therapeutic approaches are available, blocking oncomiRs or restorive tumor
suppressor-miRs. Anti-miRNA oligonucleotides (AMOs) can potentially suppress oncomiRNA activity, if the AMOs bind strongly to the miRNA and are physiologically stable.
The same idea holds true for the opposite approach, but involves the introduction of
modified oligonucleotides into cells that contain an under-expressed tumor suppressormiRNA (16).

MicroRNA Role in Prostate Carcinoma
One miRNA array screen performed by Porkka et al., analyzed 319 miRNAs in 6
prostate cancer cell lines (i.e. PC3, DU-145, and LnCap), 9 prostate cancer xenografts
samples, 4 BPH samples, 5 untreated prostate carcinomas, and 4 hormone-refractory
prostate carcinoma clinical samples revealing 51 differentially expressed miRNAs when
compared to BPH samples. Of those 51 deregulated miRNAs, 27 were down regulated
and 14 up regulated, suggesting global down regulation in cancer cells due to de-
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differentiation as seen in tumor cells compared to normal cells. All down regulated
miRNAs were found in hormone-refractory (androgen-independent), late-stage prostate
carcinomas, with a smaller portion down regulated in untreated early carcinomas.
Likewise, all up regulated miRNAs were found in hormone-refractory late-stage prostate
carcninomas with fewer up regulated in untreated early carcinomas. A few of these
differentially expressed miRNAs include the downregulated let-7 family miRNAs, miR16/miR-143, and miR-145, which target the Ras oncogene, BCL2, and oncogenes
ERBB2 and ERBB3, respectively. In addition to the 14 up regulated miRNAs, 8 of them
were shown to have increased expression in all carcinomas (miR-202, miR-210, miR296, miR-320, miR-370, miR-373, miR-498, and miR-503). Porkka et al. showed a
majority of down regulated miRNAs in prostate carcinoma, whereas a separate miRNA
array screen performed by Volinia et al. profiled 540 tissue samples from six solid
tumors, showed more up regulated miRNAs, 39, than down regulated, 6, in prostate
cancer compared to normal tissue. miR-21, miR-17-5p, miR-191, miR-29b-2, miR-223,
miR-199a-1, miR-146, miR-181b-1, miR-20a, miR-32, miR-92-2, miR-214, miR-30c,
miR-25, and miR-106a were shared with other solid cancers (35). The vast difference in
down or up regulated cancer between the two microarray screens shows the variability
between sample numbers, technical platforms, and potentially the different analytical
approaches (35). As previously noted, some miRNAs are differentially expressed in
other cancers, implicating that some cancers can share individual miRNAs, which could
be used as prognostic markers in prostate cancer. Explanations for the down regulation
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or aberrant miRNA expression points to potential defects in miRNA biogenesis
machinery or genomic alterations in cancer, as previously noted (36).
Prostate cancer has been marked by a 2.5-fold up regulation of Dicer and significant
increases of Exportin 5 in metastatic prostate cancer. In normal prostate tissue, Dicer
activity was limited to the cytoplasm of basal cells and negative in luminal cells. PIN
and prostate cancer showed Dicer in both basal and luminal cytoplasm, with PIN showing
a two fold increase in Dicer over the normal prostate. Dicer also increased with the
pathological stage of prostate cancer, with the higher levels of Dicer seen in prostate
cancer with a Gleason score greater than seven. The level of Dicer in the neoplastic
epithelial cells DU-145, LnCap, and PC-3 was compared against a non-tumorigenic cell
line, RWPE-1, with the three metastatic cell lines showing higher Dicer levels within the
cytoplasm. Although it is seen that normal prostate tissue and organ-confined prostate
cancer have relatively unchanged levels of Dicer, this is because normal prostate
epithelial cells express Dicer only in basal cells, whereas organ-confined prostate cancer
cells that express invasive properties no longer contain basal cells and all Dicer is found
within luminal cells, citing a biological significance rather than quantitative. In addition,
as prostate cancer progresses and increases in metastatic nature the Dicer level increases,
in correlation with the high Gleason score (34).

MicroRNA-155
Human miR-155 is encoded within exon 3 of the noncoding RNA BIC, a protooncogene on chromosome 21 (37). The BIC locus has been identified as a common
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retroviral integration site in avian leukosis virus-induced B cell lymphomas and shown to
promote malignant transformations upon deregulation. In addition, the BIC locus is
frequently associated with c-myc activation and preferentially found in metastatic tumors.
The expression of BIC and miR-155 is the greatest in the lymphoid tissues, including
activated B cells, T cells, macrophages and dendritic cells (38, 39), but can be seen
widespread throughout other tissues and hematopoietic tissues (40). The activation of the
BIC gene and up-regulation of c-myc has been implicated in the pathogenesis and
acceleration of lymphomas and leukemias. An elevated relative BIC RNA level and
miR-155 accumulation is seen in Hodgkin and children’s Burkitt lymphoma (41).
Transgenic mice over expressing the mouse analog of miR-155 develop high-grade B cell
neoplasms and exhibit splenomegaly and lymphopenia, suggesting the oncogenic
properties of miR-155 during dysregulation (37). In addition to the characterization of
miR-155 in immune pathologies, it has been found over expressed in lung and colon
cancer (35, 37), up regulated in pancreatic cancer progression (42), and three-fold higher
in squamous cell carcinoma of the tongue compared to normal tissue (43). Differential
expression of miR-155 in breast cancer has shown both up regulated (35) and down
regulated levels (16, 17, 33).
miR-155 has many target genes, including those involved in T cell co-stimulation,
chemotaxis (ccl-5), signaling (IKBKE), and transcriptional regulation of c-Maf (38),
BACH1 and Fos (39) (Figure 5A-C), along with many others. One studied putative
target of miR-155 is the large transcription factor c-Maf (38), belonging to the Maf
family proteins (44). Maf proteins activate transcription of target genes through the
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Figure 5. Putative miR-155 3’UTR targets. (A) Two sites in BACH1’s 3’UTR that
miR-155 targets. (B) One site in c-Fos 3’UTR that miR-155 targets. (C) Three sites in cmaf 3’UTR that miR-155 targets. Lines represent base pairing, dots represent wobble
base pairing.
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binding to the Maf responsive element on target DNA. Putative Maf targets are primarily
involved in differentiation, but recent investigation detected potential targets involved in
oncogenesis, such as c-Maf targeting the transcriptional induction of the tumor
suppressor p53 (44).
A more well known and studied target of miR-155 is the BTB and CNC homology 1
(BACH1) transcription factor (39), broadly expressed as a transcriptional repressor (37)
mapping to chromosomal region 21q22.1 (45). BACH’s role has been well studied with
relation to the breast cancer susceptibility gene BRCA1. In cells containing BRCA1, a
mutant BACH1 displayed impaired helicase activity which resulted in replication stress
and formation of DNA breaks, contributing to chromatin instability. In addition, cells
having mutant BACH1 showed increase sensitivity to ionizing radiation (46). The role of
BACH1 as a DNA repair protein was further supported in the study performed by Peng et
al., who confirmed the tumor suppressor abilities of BACH1 by noting the ability of cells
to go through DNA repair in the presence of high levels of BACH1. It was also
concluded that a decrease in BACH1 led to increased DNA damage and cellular
sensitivity to this damage, along with a delay in double-stranded DNA break repair (47).
BACH1’s potential regulation by miR-155 was studied by Cullen et al. and Renne et al.
through reporter systems using sensor constructs containing miR-155, 3’UTR targets
fused to the reporter gene luciferase. Both groups showed an inhibition of BACH1
luciferase expression in a dose dependent manner when treated with miR-155 (37) (39).
In addition, Renne et al. showed a decrease in BACH1 protein level via western blot in
B-cell lymphoma cell lines expressing high levels of miR-155 (37).
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MicroRNA-146a
The human genome contains two miR-146 genes, miR-146a on chromosome 5 and
miR-146b on chromosome 10, differing by only two nucleotides in the 3’ region of the
mature form. miR-146a expression has been widely studied in the immune system (48).
Upon LPS stimulation, a rapid induction of miR-146 level is seen in human acute
monocytic leukemia cells through Toll-like receptor 4 and a weak induction is seen in the
presence of the pro-inflammatory cytokines IL-1 receptor-associated kinase 1 (IRAK1)
and TNF receptor-associated factor 6 (TRAF6). The involvement of these two proinflammatory cytokines has been well established in toll-like-receptor and proinflammatory signaling. In addition, both IRAK1 and TRAF6 showed substantial drops
in activity in the presence of miR-146a when evaluated by reporter systems, thus they are
targets of miR-146a (19) (Figure 6). This rapid production of miR-146 coupled with a
decreased repression of signaling proposes a role for miR-146 to serve as part of a
negative feedback loop, which negates the over activation of the innate immune system
(19). miR-146 has also been found to be up regulated in the rheumatoid arthritis synovial
tissue (44, 49), papillary thyroid cancers (16, 17), CLL (33), and down regulated in germ
cell cancers (33).

Lin et al. reported a potential tumor suppressor role of miR-146a in androgen
independent prostatic cancer. A high expression of miR-146a was seen in androgendependent LnCap and PC3-AR9 cell lines and in noncancerous prostatic epithelium,
along with a progressive decrease in miR-146a during cancer progression. The over
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Figure 6. Putative miR-146a 3’UTR target. TRAF6 3’UTR. Lines represents base
pairing, dots represent wobble base pairing.
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expression of miR-146 in androgen-independent PC-3 cell line resulted in a marked
reduction in cell proliferation, invasion, and metastases. It was shown that miR-146a
targets ROCK1 protein kinase, which inhibits the transformation of androgen-dependent
cells to androgen-independent, proposing a potential tumor suppressor property of miR146 (15).

PROJECT OBJECTIVES
Prior to the start of this project, a microarray screen was conducted comparing the
expression of microRNAs between the F6 and M12 cell lines grown in vitro (2D) or
embedded in extracellular matrix (3D). microRNAs that showed significant fold
differences between the two cell lines were determined to be potential tumor suppressor
microRNAs or onco-microRNAs (oncomir). Two differentially expressed microRNAs,
which had higher expression in both M12 2D and 3D samples compared to F6, were
miR-155 and miR-146a, suggesting possible roles as oncomirs..
The purpose of this project was to evaluate the role and biological activity of the
two putative oncomirs, miR-155 and miR-146a, in a prostate cancer progression model.
The initial steps were to confirm the preliminary microarray screening data and
accurately quantitate the levels of endogenous miR-155 and miR-146a in the prostate
cancer cell lines P69, M12, and F6 using quantitative real-time PCR analysis. Secondly,
miR levels were restored in the F6 cell line to M12 levels and the resulting effect on
proliferation, motility, invasiveness, and putative target protein levels was evaluated.
Lastly, the 3-dimensional morphological appearance of these stably altered cells was
compared to the parental F6 and M12 cell lines. The overall objective of these studies
was to determine if miR-155 and miR-146a qualify as oncomiRs, which warrant further
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testing on metastatic tumor growth and metastatic behavior via injection in athymic male
mice.

MATERIALS AND METHODS
2D Cell Culture
Prostate cancer cell lines, P69, M12, and F6, were obtained in frozen aliquots at
known passage numbers from Dr. Joy Ware (Virginia Commonwealth University,
Department of Pathology, Richmond, VA). Frozen cell aliquots were thawed in a water
bath, resuspended in 10ml of media, centrifuged at 1700RPM for ten minutes to remove
DMSO, supernatant aspirated, cell pellet resuspended with fresh media and directly
plated on to 100mm x 20mm plastic tissue culture dishes (Falcon, 353003). Cells were
cultured in RPMI 1640 medium (GIBCO Invitrogen, 21870), supplemented with 5% FBS
(Invitrogen, S11150), 1% L-glutamine (Invitrogen, 25030), 0.1% ITS (insulin, 5µg/ml;
transferrin, 5µg/ml; and selenium, 5ng/ml), and 0.1% gentamicin 10mg/ml (Gibco,
15710). F6 cell media contained an additional 0.8ml of 50mg/ml geneticin (Gibco,
10131) per 200ml of media to keep selective pressure for maintenance of chromosome
19. Cultures were incubated at 37oC in the presence of 5% CO2. Media was replaced
every 48 hours and cultures passaged at 80-90% confluency.

3D Cell Culture
Stably transfected F6 cell lines were cultured embedded within a basement
membrane extract of extracellular matrix, referred to as Matrigel (R&D Systems, 343335
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005-01). Matrigel is a basement membrane extract purified from Englebreth-HolmSwarm tumor and is primarily composed of lamin, collagen IV, entactin, and heparin
sulfate proteoglycan. This compilation of extracellular proteins supports cell growth and
is essential for tissue organization, cell adhesion, migration, proliferation, and
differentiation. It also provides major barriers to invasion by metastatic tumor cells.
Matrigel was thawed on ice over night at 4oC and stored on ice at all times. One well of a
24-well plate was pre-coated with 20 µl of thawed Matrigel and placed in a 37 oC
incubator to promote polymerization. 2D cell cultures were rinsed with PBS (phosphatebuffered saline, GIBCO Invitrogen), removed from the dish with trypsin-EDTA 0.25%
(GIBCO Invitrogen, lot # 39808), resuspended in serum media, centrifuged at 1700 RPM
for ten minutes, supernatant aspirated, and cells counted using a hemacytometer. One
million cells were carefully resuspended in 500µl of Matrigel on ice, transferred onto the
pre-coated well, and then placed in the incubator for 15 to 30 minutes to allow
polymerization of the matrigel-cell suspension. Finally, 250µl of media containing 5%
Matrigel was applied on top of the cell suspension and incubated for up to 12 days. The
top layer of media was replaced every two to three days with 250µl of fresh serum media
with appropriate antibiotic selection.

Cell Counting
Cells were rinsed with PBS and removed from culture dishes by trypsin-EDTA
digest. The trypsin-cell suspension was neutralized with fresh media containing FBS and
centrifuged at 1700RPM for 10 minutes. Cell pellets were resuspended in 1mL of media.
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Resuspended cells (100µl) were treated with 900µl of Tryptan-blue solution and loaded
on to a hemacytometer. The average live-cell count was used to estimate the total
number of cells present and the amount of cell-containing media needed to ensure the
correct experimental number of cells needed for transient and stable transfection, 3DMatrigel growth, and cell proliferation assays.

Oligonucleotide Design
The mature DNA sequence of human miR-155 and the precursor DNA sequence
of human miR-146a was identified using online software (http://microrna.sanger.ac.uk/,
2008) and appropriate oligonucleotides designed (see, bold Table 1.). miR-155
oligonucleotides were manufactured by Invitrogen, using Hind III and Bgl II compatible
ends for ligation into the pH1-RNApuro (ph1pa) plasmid vector (Figure 7). The miR146a oligonucleotides were manufactured by Integrated DNA technologies, containing a
5’- BamH I restriction site overhang on the top strand, and 5’- EcoR I restriction site
overhang on the bottom strand (see bold, Table 1), which allowed for directional cloning
of the annealed oligonucleotides into the pSiren-RetroQ vector (Clontech, 631526)
(Figure 8). In addition, the designed oligonucleotides contained the recommended 7-9
nucleotide hairpin loop sequence, 5’-TTCAAGAGA-3’, as outlined in the Clontech
protocol (PT3739-1). The Xba I restriction site (5’-TCTAGA-3’) was also incorporated
on both top and bottom strand to create a novel restriction site for confirmation of
plasmid insert. Correct cloning of DNA insert was confirmed through sequencing.
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Table 1. Designed oligonucleotides of mature miR-155 and precursor miR-146a.

miR-155 Sense

5’-GATCCCCTTAATGCTAATCGTGATAGGGGTTTT-3’

miR-155 Antisense 5’-AGCTAAAACCCCTATCACGATTAGCATTAAGGG-3’5’
miR-146a Sense

5’GATCCGTGAGAACTGAATTCCATGGGTTTTCAAGAGA
AACCCATGGAATTCAGTTCTCATTCTTTTTTTCTAGAG-3’

miR-146a
Antisense

5’AATTCTCTAGAAAAAAAGAATGAGAACTGAATTCCAT
GGGTTTCTCTTGAAAACCCATGGAATTCAGTTCTCACG3’
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Figure 7. pH1-RNApuro vector.
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Figure 8. pSiren-RetroQ vector.
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Oligonucleotide Ligation
Each designed oligonucleotide pair, miR-155 forward and reverse and miR-146a
forward and reverse, were spun down at 8,000RPM for five minutes and then diluted with
1X Tris-EDTA (1X TE) Buffer pH 7.5 to achieve a final concentration of 100 µM. Five
microliters of each oligonucleotide pair were mixed together (10µl total volume, 50µM
concentration) and annealed by the following thermal conditioning: 95oC for 2 minutes,
72oC for 2 minutes, 37oC for two minutes, 25oC for two minutes. Samples were then
stored at -20oC for further DNA ligation experimentation.

Restriction Endonuclease Digestion
Restriction endonuclease digestions were performed on both pH1-RNApuro and
pSiren-RetroQ plasmid vectors. 10uL (200ng) of pSiren-RetroQ plasmid vector
(Clontech, 631526) was digested for 12 hours in a 37oC water bath with 2µl 10X NEEcoR I buffer (New England Biolabs, Ipswich, MA), 4µl of H2O, 2µl 10 X BSA, and 1µl
of both BamH I and EcoR I (New England Biolabs). After digestion, the mixture was
placed on heat block at 80oC for 20 minutes to inactivate restriction enzymes. The pH1RNApuro vector was digested under the same conditions with 10uL of the vector, 2µl
10X NEbuffer 2 (New England Biolabs), 2µl 10 X BSA, 1µl of both Hind III and Bgl II
(New England Biolabs, Ipswich, MA), and 4µl of H2O.
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DNA ligation
In a sterile microcentrifuge tube the double stranded oligonucleotides were diluted
to a 0.5µM concentration. All reagents are from New England Biolabs, Ipswich, MA,
unless otherwise noted. Ligation was carried out for both microRNA-vector pairs by
combining 2µL of digested linearized vector (25ng/µl), 1µl of diluted annealed double
stranded oligonucleotide (0.5µM), 1.5µl 10X T4 DNA Ligase Buffer, 0.5µl BSA
(10mg/mL), 0.5µl T4 DNA ligase (400U/µl), and 9.5µl nuclease free water. A control
ligation for each was also carried out, replacing the 1µl of diluted annealed
oligonucleotide with 1µl of nuclease free water. All ligation mixtures were incubated at
room temperature for three hours, then immediately put on ice or stored at -20oC.

Bacterial E. Coli Transformation
One hundred microliters of competent E. Coli bacterial cells stored at -80oC were
thawed on ice for ten minutes. Five microliters of ligation product (pSiren-Retroq+miR146a, pSiren control, pH1-RNApuro+miR-155, and pH1-RNApuro control vectors) were
added to individual thawed cell aliquots and incubated on ice for 15 minutes. Following
incubation, cells were heat shocked in a water bath at 42oC for 15 seconds, then returned
to ice for two minutes. The transformation reaction was diluted with 250µl of LuriaBertani (LB) media and incubated at 37oC for 60 minutes while being shaken at
250RPM. Two-hundred microliters of the mixture was plated on LB agar plates
containing 10µg/ml ampicillin, set upright for 15 minutes, then placed upside-down and
incubated for 12 hours at 37oC.
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Small Scale DNA Preparation
After E. Coli transformation, many single colonies from the freshly streaked
experimental plates were selected to inoculate individual cultures of 5ml LB media
supplemented with 5µl ampicillin and incubated at 37oC for 12 to 16 hours with shaking
at 250RPM. Following incubation, the expanded colonies were pelleted in a
microcentrifuge tube by centrifugation at 13,000RPM at room temperature for three
minutes. After aspirating the supernatant from the cell pellets, the plasmid DNA was
purified using QIAprep Miniprep Kit (QIAGEN, 27106) per manufacturer recommended
protocol. The purified DNA was stored at -20oC.

Agarose Gel Electrophoresis
Each experimental vector clone was analyzed by digestion with appropriate
restriction enzymes. All reagents and restriction enzymes are from New England
Biolabs, Ipswich, MA , unless otherwise noted. Purified pSiren-RetroQ+miR14a DNA
(1µg) from the small scale DNA preparation was combined with 9uL of nuclease free
water, 2µL of NEBuffer 2, 2µL 10X BSA, 1 µL Xba I, 1µL Afl III, and incubated
overnight in a 37oC water bath. pH1-RNApuro+miR-155 purified DNA (1µg) was also
digested overnight in combination with 7.5µL nuclease free water, 2µL NEBuffer 2, 2µL
10X BSA, and 0.75µL of each Xho I, Nhe I, and Hind III. A 1% agarose gel was
prepared using 1.0g agarose in 100mL 1X Tris/Borate/EDTA (1X TBE), along with 2µL
of ethidium bromide. Each digested mixture (20µl) was placed into individual wells and
electrophoresed at 100V. A 1-kilobase DNA ladder was included. The gels were
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evaluated underneath ultra-violet light. The vector containing the correct size and
number of bases was selected for DNA sequencing.

Sequencing
The specific clone selected from agarose gel analysis was sent for sequencing at
MCV-VCU Nucleic Acids Research Facilities (NARF). Positive sequencing of the
pSiren-RetroQ+miR-146a and pH1-RNApuro+miR-155 vectors containing the
appropriate insert DNA was confirmed.

Plasmid Purification
Plasmid DNA from the correctly sequenced pH1-RNApuro+miR-155 vector,
along with pH1-RNApuro vector without insert, was used to transform competent E.
coli. Five colonies from the freshly streaked plate were used to inoculate a large scale
250ml LB liquid culture. Following overnight incubation with shaking at 37oC, the
plasmids were purified using the Marligen High Purity Maxiprep Kit and manufacturer
protocol (Marligen Biosciences, 11452) to obtain approximately 750µg of purified DNA.
Plasmid DNA for the correctly sequence pSiren-Retroq+miR-146a, along with
pSiren-RetroQ-NTC vector, was purified by Qiagen miniprep protocol, as previously
outlined, without need for a larger scale purification.
The 3’-UTR luciferase reporter constructs PLSV40-Bach1, PLSV40-Fos, and cMaf wild type, provided by Dr. Cullen and Dr. Rodriguez, respectively, were received
spotted on filter paper. Each spot was partially excised using a sterile razor, placed with
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40µl of 1 X TE Buffer into a microcentrifuge tube, and vortexed vigorously. Five
microliters of the solution was transformed in 100µl of competent E. Coli cells, followed
by inoculation and plasmid purification via the Marligen high purity maxiprep isolation
kit.

Generation of Stably Transfected Cell Lines
F6 cells were transfected with the appropriate vector constructs, using TransITLT1 transfection reagent (Mirus, MIR 2300). F6 cells were transfected at a confluency of
60-70% by pH1-RNApuro or pSiren-RetroQ vector constructs in a 3:1 ratio of TransITLT1 reagent (3µl): vector DNA (1µg), for 48 hours in serum media, as outlined by the
Mirus protocol. Transfected cells were selected by antibiotic resistance using 300ng/ml
of puromycin for three days or until all F6 cells containing no transfected plasmid were
completely killed by puromycin selection. Frequent media changes were conducted to
remove lysed cells.
Following high dose antibiotic selection, the remaining transfected F6 cells were
gently trypsinized with diluted 0.05% Trypsin-EDTA and placed in a succession of 6well plates, 60mm dishes, then 100mm plastic tissue culture dishes, creating a
heterogeneous mixture of stably transfected cells. These cells were continually subjected
to a maintenance antibiotic dose of 100ng/ml of puromycin.
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RNA Purification
mRNA was isolated from p69, M12, F6, F6+pH1PA-155, F6+pH1PA,
F6+pSiren-146a, and F6+pSiren-NTC cells. Total RNA was isolated from frozen or
fresh cell pellets consisting of 1-2x106 cells using the mirVanaTM miRNA Isolation Kit
(Ambion, 1560). The protocol was followed precisely as outlined by mirVanaTM. The
concentration of purified RNA was determined by dissolving 5µl of the isolated total
RNA sample in 95µl of RNAse-free water. The absorbance of the diluted sample was
measured at 260nm (A260) in a Smart Spec 3000 spectrophotometer (Bio Rad). To
determine RNA concentration in microgram per milliliter, the ratio of A260/A280 was used
to assess the RNA purity (1.8-2.1 ratio range for highly pure RNA). The remaining RNA
was stored at -80oC for future analysis.

cDNA Synthesis, Real Time- PCR
The reverse transcription reaction was conducted on P69, M12, F6, F6+pH1PA155, F6+pH1PA, F6+pSiren-146a, and F6+pSiren-NTC cell lines utilizing the total RNA
previously described. The RT-PCR reaction was conducted using the Taqman
MicroRNA Reverse Transcription Kit (Applied Biosystems, 4366596) and RoboCycler
thermal cycler (Stratagene Cloning Systems, 400860). All reagents used in the RT-PCR
reaction are from the Taqman kit, unless otherwise noted. The total RNA previously
isolated, was diluted using elution buffer to obtain a 0.1 µg/µl concentration. Small
eppendorf tubes (0.5ml) were used containing 200ng (2µl) of RNA from each respective
cell line, 4.162µl of nuclease free water, 0.15µl of 100mM dNTPs, 1.5µl of 10x RT
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Buffer, 3 µl of experimental 5X TaqMan MicroRNA RT Primer (TaqMan MicroRNA
Assay, hsa-MiR-146a, 4373383; or hsa-MiR-155, 4373124), 3µl of control 5X TaqMan
MicroRNA RT Primer (Applied Biosystems, RNU48, 4373383), 0.188µl of RNase
Inhibitor, and 1µl of MultiScribe Reverse Transcriptase, for a total volume of 15µl. Each
tube was gently mixed, quickly spun down, and then subjected to 30 minutes at 16oC, 30
minutes at 42oC, and 5 minutes at 85oC to inactivate reverse transcriptase. An additional
30µl of nuclease free water was added to the 15µl total, for a final 45µl total, and then
stored at -20oC to -80oC for future PCR reactions.

Qualitative RT-PCR (qRT-PCR)
To evaluate the presence of the specific microRNAs (146a and 155) within the
cDNA samples, 3µl of RT-PCR cDNA, 1µl of 20X Taqman MicroRNA Assay Primer
(hsa-miR-146a, hsa-miR-155 or hsa-RNU48), 7µl of sterile deionized water, and 10µl of
2X Taqman Universal PCR Master Mix was placed in triplicates in a 96-well plastic plate
(Applied Biosystems, 4303327), for a total volume of 20µl per well. Both experimental
microRNA and control RNU48 primer pairs were run together in triplicates. The 96-well
plate was prepared on ice in unlit conditions, and then centrifuged at 1,000RPM for 5
minutes. The 20µl reactions were incubated in an Applied Biosystems 7300 Real-Time
PCR machine for 2 minutes at 50oC, 10 minutes for 95oC, followed by 40 cycles of
denaturation for 15 seconds at 95oC and annealing/extension reaction for 60 seconds at
60oC. Data collection was obtained at the first step of stage three, the 15 seconds of
denaturation at 95oC.
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The threshold cycle (Ct) is the PCR cycle at which fluorescence of the primer
rises above a minimal threshold. In order to confirm the presence of miR-155, miR-146,
and RNU48 among the cell lines, analysis of the Ct was performed based on the
comparison Ct method. The equation is,
Ct = 2-∆Ct, sample - ∆Ct, reference
A lower Ct value indicates a larger amount of starting material, i.e. more target
mRNA. The relative quantification of the target gene was normalized to the internal
control gene, RNU48, to allow for variations in RNA integrity, RT-PCR efficiency, and
sample loading.

DNA Transient Transfection and Luciferase Promoter Assays
Luciferase promoter assays were conducted using the Dual-Luciferase Reporter
Assay System (Promega, E1910) and TransIT-LT1 transfection reagent. The reporter
assay system utilizes the measurements of two individual reporter enzymes, the
experimental firefly luciferase and the control renilla luciferase. The internal control
minimizes experiment variability, due to differences in cell viability or transfection
efficiency.
Approximately 3x105 cells were plated in triplicates in 6-well plates and grown
over night to a confluency of 75%. The transfection was carried out per Mirus protocolincubating cells with reporter plasmid (0.8µg) and renilla plasmid (0.2µg) for 48 hours.
After incubation, each well was washed twice with PBS, cells trypsinized, collected in
1.5mL eppendorf tubes, and pelleted. The cells pellets were washed twice with PBS and
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repelleted with complete aspiration of PBS wash. Following the PBS wash, cells were
lysed with 200µl 1xPassive lysis buffer (PLB) and incubated in liquid nitrogen for 5
minutes followed by incubation in a 37oC water bath for 5 minutes. As described by
Promega protocol, the PLB and lysed cells were centrifuged and supernatant collected for
luciferase analysis. Firefly and renilla luciferase readings were recorded on a
luminometer. Twenty microliters of PLB lysate was injected into luminometer tube,
followed by sequential injection of 100µl of LAR II and Stop&Glo reagent, with
measurements after each injection. The final luciferase reading for each experimental
well was a ratio of firefly luciferase and the partnered renilla luciferase reading and
calculated as,

Cell Proliferation Assay
The effect of stably transfected microRNA-155 and microRNA-146a on the
growth of the F6 prostate cancer cell line was assessed using the WST-1 Cell
Proliferation Reagent (Roche, 11644807001). Prostate cancer cell derivatives (M12, F6,
F6+pH1-RNApuro-155, F6+pH1-RNApuro, F6+pSiren-146a, and F6+pSiren-NTC) were
plated in 96 well plates (BD Falcon) at a concentration of 1x103 cells per well. Each cell
line was plated in eight well in a total volume of 100µl per well (1x103 cells/100µl),
leaving empty wells to serve as experimental blanks, and incubated at 37oC in CO2 5%.
One plate was read every other day, beginning with the first day following the initial
plating and set as day 0. On assay days all media was carefully aspirated from all wells,
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100µl of serum-free media was added to each well, and 10µl of WST-1 Cell Proliferation
Reagent (10% of media amount) was added to all experimental cell and experimental
blank wells, and then incubated at 37oC for two hours. The absorbance of each well was
measured using an Elisa 312e Microplate Bio-kinetics Reader (BIO-TEK Instruments) at
450nm. Media was carefully aspirated and replaced every two to three days in remaining
plates. The absorbance of each cell line was averaged and normalized to the blank of
each assay day, using the following equation,

Migration Assay
Cells were detached using 2-3mL of cell stripper (Cellgro, 25-056-CI), washed in
serum-free media, and pelleted. The pellets were resuspended in serum-free media to a
density of 1x105 cells/ml. A cell suspension (2.5x104 cells in 250µl) was added to the
upper chamber of an 8.0um pore size Transwell filter insert (Corning Inc., 3422) and
750µl of supplemented media (10% FBS and 2ng/ml EGF) was placed in the lower
chamber of each well. Cells were incubated at 37oC for 48hr. Following incubation, the
media from both lower and upper chambers was aspirated. Cells were fixed by the
addition of 1ml of 0.1% glutaraldehyde in PBS to the bottom chamber for 20 minutes at
room temperature and then aspirated. The filter was stained with 0.1% crystal violet in
PBS for 30 minutes at room temperature. The stain was thoroughly rinsed with deionized
H2O. Each filter was cut with a sterile blade, placed on a glass microscope slide, and the
non-migratory cells on the upper surface of the filter were gently scrapped off using a Q-
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tip. The filter was then mounted a slide using Permount and cells on the underneath side
of the filter were counting in five random fields per filter at 400x magnification.

Invasion Assay
The same protocol was followed as with the migration assay with one additional
step. A Matrigel-serum-free mixture was added on top of each Transwell filter insert in
order to assay the invasive properties of cell lines. Twenty-five microliters of a 1:10
dilution of Matrigel in serum-free media was placed on top of the Transwell filter and
allowed to incubate at 37oC for twenty minutes, sufficient time for adequate
polymerization. Cells were added on top of the polymerized Matrigel and all other steps
in migration assay remained as previously discussed.

3D Immunoflourescence
Serum media on top of polymerized Matrigel-cell mixture was aspirated. The
Matrigel-cell mixture (40µl) was removed by a pipette tip and 10 µl was placed into each
chamber of a 4-well chamber glass slide (Lab-Tek, 154526). The slide was allowed to
completely air dry and fixed using 500µl of a 1:1 mixture of methanol/acetone at -20oC
for 10min. The methanol/acetone was discarded and the slide left to air dry. Once
completely dry, the slide was stored at -80oC or used immediately for staining.
Each well was rinsed three times with 500µl of PBS (pH 7.4) for five minutes
with gentle shaking. To increase cell permeability 500µl of 0.5% Triton is applied to
each well for 30 minutes with shaking. Triton was aspirated and the plate is washed with
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1ml of PBS for 5 minutes. IF buffer (130mM NaCl, 5mM Na2HPO4, 3.5mM NaH2PO4,
7.7mM NaN3, 0.1% BSA, 0.2% Triton-X 100, 0.05% Tween-20) was prepared. 400µl of
IF buffer + 10% goat serum was added to each well and shaken at room temperature for
1h to provide a primary block. The primary block was aspirated, then each well was
incubated with 200µl/well of a secondary block antibody (IF buffer + 10% goat serum +
20µg/ml goat anti-mouse F(ab’)2 fragment) for 30-40 minutes. The primary antibodies,
α-6 integrin (Chemicon, MAB1378), β-1 integrin (Chemicon, MAB1981Z), β-4 integrin
(Chemicon, MAB2058), vimentin (Sigma, V6630), E-cadherin (BD BioSciences), and βcatenin (Santa Cruz Biotech, H-102) were diluted 1:200, 1:200, 1:200, 1:200, 1:50, and
1:100, respectively, in the secondary blocking solution and incubated over night (15-18h)
at 4oC. Following steps were carried out avoiding light exposure. Each chamber was
rinsed with IF buffer for 10 minutes three times with gentle rocking. 200µL of IF buffer
+10% goat serum + secondary antibody was added to each well and incubated at 4 oC for
40-50 minutes. Mouse secondary antibody had green fluorescent dye and rabbit had red
fluorescent dye. Each well was subsequently rinsed three times for 10 minutes each with
IF buffer and gently rocked at room temperature. One drop of DAPI nuclei stain was
applied to each well, a glass cover slip added, and incubated over night at room
temperature. The cover slip was mounted with clear nail polish and either stored at -80oC
or evaluated immediately under confocal microscope.
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3D Cell Harvest
A mixture of 10mL PBS with 1% 0.5M EDTA and 1% protease inhibitor was
chilled on ice. The top layer of media was aspirated and 5mL of the chilled PBS solution
was added to the Matrigel-cell mixture and dislodged by gentle scraping with a sterile
pipette tip. The PBS/EDTA/matrigel-cell mixture was placed into a 50mL tube and
incubated in an ice bath for 1.5 hours while rocking. After incubation the mixture was
centrifuged at 1,000 RPM for 10 minutes at 4oC followed by careful aspiration of the
supernatant. The remaining 5mL of the PBS/EDTA/protease inhibitor mixture was used
to wash the pellet, followed by repeated centrifugation. The pellet was flash frozen in
liquid nitrogen and stored at -80oC or used immediately for RNA, DNA, or protein
isolation.

Whole Cell Protein Extract (WCE)
Cell pellets were obtained and lysed in 4% SDS in 1X PBS with protease inhibitor
(Sigma, St. Louis, MO), the amount varied based on cell pellet size. The SDS-cell
mixture underwent sonification until the pellet was completely dissolved and the solution
no longer viscous. Following sonification, an equal volume of 1xPBS was added to each
tube reducing the SDS concentration to 2%. Lysates were centrifuged at 12,000RPM for
10 minutes at room temperature, supernatant carefully collected into fresh
microcentrifuge tubes and protein concentration measured using BioRad Dc Protein
Assay Kit (BioRad, Hercules, CA). Five microliters of each protein extract was mixed
with 100µl of Bio-Rad Dc Protein Assay Reagent A (BioRad, 500-0113) that contained
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2µl of Bio-Rad Dc Protein Assay Reagent S (BioRad, 500-0115), followed by the
addition of 800µl of Bio-Rad Dc Protein Assay Reagent B (BioRad, 500-0114). The
protein assay solution (800µl) was added to plastic spectrophotometer curvettes and read
at 750nm against an established standard curve to obtain protein concentration. Each
protein extract (60µl) was placed into a fresh microcentrifugation tube, 20µl of a 4X SDS
loading buffer was added, heated at 95oC for five minutes, then immediately put on ice
and placed at -20oC.

Western Blot
WCE protein (60µg) from selected cell lines was analyzed on a 4-15% Tris-HCl
polyacrylamide gel (BioRad, 161-1158), electophoresed at 100 volts in 1xSDS running
buffer (Tris 3.03g, glycine 14.4g, SDS 1g) for one hour. The gel was transferred onto
nitrocellulose paper at 30 volts for twelve hours in the presence of 1x transfer buffer (Tris
3.03g, glycine 14.4g) at 4oC. The membrane was washed in 1X Tris buffered Saline (1X
TBST)(25mM Tris-HCl pH 7.5, 0.137M NaCl, 2.7mM KCl) three times for 5 minutes
with gentle rocking, followed by incubation in 5% non-fat milk for 1 hour at room
temperature with rocking. The membrane was again washed in 1xTBST three times for
five minutes, followed by incubation in 5% non-fat milk with primary antibody BACH1
(Zymed, 37-0900) in a 1:500 dilution for 12 hours at 4oC. The membrane was washed in
1xTBST as previously stated, followed by addition of the secondary antibody in 5% milk
for one hour at room temperature. The membrane was washed three more times in
1xTBST. The membrane was then rinsed with equal amounts (200µL) of
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chemiluminescence oxidizing reagent and enhanced luminal reagent (Western
Lightning™, NEL104 and NEL105), allowing excess reagent to drip off, placed onto a
glass plate, and developed in the dark room at the desired exposure time. The same
membrane was used over by adding stripping solution (100mM glycine, 10mM βmercaptoethanol (375µL β-mercaptoethanol/500mL) three times for 30 minutes at room
temperature, followed by 1X TBST washing.

Statistics
Following data analysis the standard deviation was calculated using the following
equation, n represents the sample size

.
Standard error was then calculated using the following equation, where n is the sample
size,

.
Each qRT-PCR reaction was run in three to four sets of triplicates, the luciferase assay in
a single set of triplicates, the migration and invasion assays in two sets of triplicates, and
the cell proliferation assay in a single set of eight samples. Graphical analysis depicts
plus and minus standard error.
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RESULTS
Differential microRNA expression via microarray analysis
Microarray analysis evaluating microRNA (miR) expression in the metastatic
M12 cell line versus its non-metastatic, barely tumorigenic variant, F6, in both 2D (in
vitro) and 3D (grown in extracellular matrix), was performed by Drs. Xueping Zhang and
Zendra Zehner using established protocols via Applied Biosystems Taqman MicroRNA
Assay System (Virginia Commonwealth University, Richmond, VA). Unpublished data
showed the differential expression of miRs considered either as tumor suppressors (high
in F6 and low in M12) or oncomiRs (high in M12 and low in F6). The Ct value
represents the amplification cycle number at which the miR RNA level accumulates past
a set threshold and further correlates to the absolute amount of specific mRNA present.
A low Ct value represents a large abundance of mRNA; a higher Ct value represents a
lower abundance. Applied Biosystem’s software indicates that a C t value ≤ 32 is
considered valid. Each Ct value was normalized to an internal control gene, RNU48.
The expression fold difference of the normalized Ct values between cell lines was
determined (RQ value). miR-155 showed a 2.0-fold higher expression level in M12s
grown in 2D and a 3.6-fold higher expression in M12 grown in 3D compared to F6. miR146a showed a 272.6-fold higher expression in M12 grown in 2D and a 3351.8 fold-
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higher difference in the M12 grown in 3D samples, compared to F6 (Table 2). Thus,
miR-155 and miR-146a show expression patterns typical of potential oncomiRs. miR146a had some Ct values above the recommended Ct cut off, therefore these normalized
RQ values are potentially over-inflated and require further validation.

miR-155 has a higher endogenous expression in metastatic M12
Quantitative real-time PCR (qRT-PCR) was performed to confirm the preliminary
microarray screening data, which showed an up regulation of miR-155 in the M12 cell
line. qRT-PCR permits the accurate detection and quantification of endogenous levels of
mature miR-155 in the parental P69, metastatic M12, and non-metastatic F6 variant cell
lines using a specific fluorescent Taqman probe and primers specific for miR-155. The
M12 cell line had an approximate 10-fold higher miR-155 expression compared to F6
and a 17-fold higher expression compared to P69 (Figure 9). Thus, miR-155 was up
regulated in the M12 cell line to an even higher level than the initial microarray data
demonstrated and thus, could be potentially viewed as an oncomiR.

Over expression of mature miR-155 in F6 cells
To evaluate the potential metastatic nature of miR-155 an expression vector
containing the mature miR-155 sequence was cloned into the F6 cell line and compared
to M12 in subsequent experiments. Following cloning, the ph1pa-155 vector was
transfected into F6 cells (F6+ph1pa-155) as well as the vector alone (F6+ph1pa) to serve
as a vector control. After drug selection the stably transformed cells, F6+ph1pa-155 and
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Table 2. miRs are differentially expressed in prostate cancer sublines. A microarray
screen evaluating the differential expression of miRs between two prostate cancer cell
lines, M12 (metastatic) and F6 (non-metastatic), in both 2D (in vitro) and 3D (grown
embedded in extracellular matrix). The Ct values below represent the raw value and
normalized against an internal control. The RQ value is the fold difference detected
between the normalized M12 and F6 expression level.
microRNA M12-2D
Ct Value

F6-2D Ct
Value

M12/F6
2D RQ

M12-3D
Ct Value

F6-3D Ct
Value

M12/F6
3D RQ

miR-155

27.9

28.9

2.0

28.0

29.2

3.6

miR-146a

40.0

31.9

272.6

25.6

37.2

3351.8
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Figure 9. miR-155 is up regulated in the metastatic M12 cell line. The endogenous
levels of the mature miR-155 in the prostate cancer progression cell lines, P69, M12, and
F6, was evaluated using specific Taqman qRT-PCR. Each sample was run in four sets of
triplicates and normalized to RNU48, with bars representing the standard error. Italicized
values represent fold-difference compared to P69; bold values represent fold-difference
compared to F6.

60
F6+ph1pa, were obtained. The mRNA level of mature miR-155 in the stably transfected
cell lines grown in tissue culture (2D) was measured via Taqman qRT-PCR and
compared to the endogenous levels (Figure 10). F6+ph1pa-155 had a 20-fold higher and
11-fold higher expression compared to P69 and F6, respectively. Importantly, the miR155 expression in F6+ph1pa-155 was at a physiological level comparable to M12. Stable
transfectants with vector alone, F6+ph1pa, showed no significant fluctuation of miR-155
expression compared to unaltered F6 cells.
The miR-155 expression in F6, M12, and F6+ph1pa-155 following their growth
embedded (3D) in the extracellular matrix Matrigel was evaluated via specific Taqman
qRT-PCR. These experiments were done to determine how the addition of Matrigel, a
cell culture substrate rich in extracellular proteins as found in stroma of the prostate
gland, would affect miR expression. There was a 5-fold higher expression in M12
compared to F6, and a 3-fold higher expression in F6+ph1pa-155 compared to F6 (Figure
11). Although the miR level was higher in 3D for F6, M12, and F6+ph1pa-155
compared to 2D, the fold difference was considerably lower. These results suggest the
extracellular environment is having an effect on miR gene expression.

Cell proliferation assay investigating affects of miR-155
To determine if miR-155 had an effect on growth, a cell proliferation assay was
performed on F6, M12, F6+ph1pa-155, and F6+ph1pa by applying the WST-1 Reagent.
WST-1 measures the metabolic activity of cells through the conversion of WST-1 into a
soluble formazan salt, producing a color change in the media, which directly correlates
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Figure 10. Stable expression of miR 155 in F6 cells was comparable to M12
expression level. The over expression of mature miR-155 in F6+ph1pa-155 was
confirmed by specific Taqman qRT-PCR. In all cases, four separate samples were run in
triplicate and normalized to the internal control RNU48, with bars representing standard
error. Italicized values represent fold-difference compared to P69; bold values represent
fold-difference compared to F6.
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Figure 11. miR-155 is up regulated in M12 and F6+ph1pa-155 when grown in
extracellular matrix. M12 and F6+ph1pa-155 miR-155 expression was compared to F6
when grown embedded in extracellular matrix (3D). Three separate 3D samples of each
cell line were run in triplicates and normalized to the internal control RNU48, with bars
representing standard error. Bold values represent fold-difference compared to F6.
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with the cell number. The color change was evaluated using an ELISA plate reader at
450nm.
A comparison of the linear trendline positive slope (0.563 and 0.633) between
M12 and F6+ph1pa-155, respectively, showed similar proliferation rates. Likewise, F6
and F6+ph1pa displayed similar proliferation rates with a positive slope of 0.268 and
0.312, respectively. F6 and F6+ph1pa had substantially slower growth than M12 and
F6+ph1pa-155 (Figure 12). M12 and F6+ph1pa-155 began to plateau between day 10
and 12 as the cells reached 100% confluency. F6 and F6+ph1pa continued to proliferate
for twelve days (length of assay). It would be suspected to see a plateau in proliferation
of F6 and F6+ph1pa cells at the same WST-1 absorbance level of M12 and F6+ph1pa155 cells if the assay was carried out for a longer period of time. This would reflect the
extended time it would take the slower proliferating cells to reach confluency. More
importantly, F6 cells over expressing miR-155 proliferated at a rate similar to the
metastatic M12 subline.

miR-155 affects the motility and invasiveness of F6 cells
The motility of M12, F6, F6+ph1pa-155, and F6+ph1pa was evaluated using a
dual chamber system (Figure 13). Each cell line (2.5x104 cells) was plated in serum
starved media and placed into the upper chamber on top of a Transwell filter insert with
serum rich, EGF-contiaing media, serving as a chemoattractant, placed in the lower
chamber. Cells were incubated for 48hr, fixed, stained, mounted on glass microscope
slides, and counted in five random fields per filter at 400X magnification. The motility
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Cell Line
M12
F6+ph1pa-155
F6
F6+ph1pha

Linear Trendline
Y= 0.563x - 1.021
Y= 0.633x - 1.137
Y= 0.268x - 0.437
Y= 0.312x - 0.569

Figure 12. miR-155 over expression affects the proliferation of F6. The cell
proliferation of M12, F6, F6+ph1pa-155, and F6+ph1pa was observed over twelve days
by measuring the WST-1 absorbance at 450nm. Each cell line had eight samples
analyzed per assay and normalized to wells without cells (blank), with bars representing
standard error.
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A.

B.

Figure 13. Over expression of miR-155 affects the motility and invasiveness of the
F6 subline. (A) F6, M12, F6+ph1pa-155, and F6+ph1pa cells were plated in the upper
chamber of a Transwell insert, subjected to chemoattractants in the lower chamber, and
then allowed to migrate for 48h. 5 random fields per filter (thirty in total) at 400X
magnification were counted. Bars represent standard error. (B) F6, M12, F6+ph1pa-155,
and F6+ph1pa were plated on top of Matrigel-coated Transwell inserts, subjected to
chemoattractants in the lower chamber, allowed to migrate for 48h, and evaluated as in
panel A, with bars representing standard error. Bold values represent fold-difference
compared to F6.
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of M12 and F6+ph1pa-155 was comparable, with an average of 113.8 and 110.5
migratory cells per field, respectively. Likewise, F6 and F6+ph1pa were comparable
with 31.7 and 22.5 average cells per field, respectively. More importantly, F6+ph1pa155 cells were approximately 3-fold more migratory than the parental F6 subline and
matched the enhanced motility of the highly tumorigenic M12 subline (Figure 13A.).
The invasiveness of M12, F6, F6+ph1pa-155, and F6+ph1pa was evaluated using
the same dual chamber system described above, but with cells plated on top of a Matrigel
coated Transwell filter. The ability of cells to invade the matrigel layer and attach to the
bottom of the filter measures invasiveness. F6 and F6+ph1pa were nearly non-invasive,
averaging only 0.4 invading cells per field, whereas M12 and F6+ph1pa-155 had 155.6
and 151.5 invading cells per field (Figure 13B.). M12 and F6+ph1pa-155 were not only
more invasive than F6 and F6+ph1pa, but more cells moved in the presence of a Matrigel
barrier compared to a filter alone in the migration assay. This is a strong representation
of the possible enhanced metastatic behavior of these cells in vivo since Matrigel mimics
the microenvironment of the prostate gland.

miR-155 affects expression of sensor constructs containing putative 3’UTR targets
miRs exert their biological affect by down regulating mRNA through degradation
or translation repression of target mRNAs. By either method, the end result
is a decrease in the amount of protein for that specific mRNA target. For example, if a
cell has a high miR level, it would be expected to show lower protein levels coming from
its target mRNA. Conversely, if a cell has a low miR level, it should have high protein
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levels. To determine if the differential expression of miR-155 contributes to the
regulation of protein expression, luciferase assays were conducted using a plasmid
containing the putative 3’-UTR target sequence fused to the luciferase cDNA under
control of a ubiquitous promoter. Three putative 3’-UTR targets, BACH1, c-Fos, and cmaf, were chosen based on matches provided by multiple online miR-target databases
(TargetScan, PicTar, and Miranda) and confirmed by reports the in literature (36, 37).
An approximate 3-fold lower reporter activity was detected for luciferase fused to
BACH1’s 3’-UTR target sequence in F6 cells over expressing miR-155 and parental
M12, compared to F6 and F6+ph1pa (Figure 14A.). Similar luciferase sensor constructs
containing the 3’-UTR from c-Fos showed an approximate 3-fold and 2-fold decrease in
luciferase activity in M12 and F6+ph1pa-155, respectively, compared to F6 and
F6+ph1pa (Figure 14B). The c-maf luciferase sensor construct depicted a 3.4-fold and 2fold decrease in luciferase activity in M12 and F6+ph1pa-155, respectively, compared to
F6 and F6+ph1pa (Figure 14C.). From these results it was concluded that the over
expression of miR-155 in F6 does indeed exert a biological effect on sensor construct
protein levels in these prostate cancer cell line variants.

miR-155 regulates the expression of endogenous BACH1 protein levels
As seen in the qRT-PCR results, miR-155 was selectively down regulated in the
non-metastatic prostate cancer cell line and up-regulated in the metastatic cell line. Also,
the luciferase sensor construct showed a down regulation of BACH1 luciferase activity in
M12 and F6+ph1pa-155 compared to F6. To determine if miR-155 was involved in the
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Figure 14. The expression of putative miR-155 targets is down regulated in M12
and F6+ph1pa-155. (A) BACH1 sensor activity. (B) c-Fos sensor activity. (C) c-maf
sensor activity. Each sample was run in one set of triplicates. Each bar represents
standard error. Bold values represent fold-difference compared to F6.
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repression of endogenous BACH1, BACH1 protein levels were evaluated in whole cell
extracts from three different cell lines, which differed in their degree of miR-155
expression. As expected, cell lines which had more miR-155, such as M12 and
F6+ph1pa-155, had decreased endogenous BACH1 levels, whereas the cell line with less
miR-155 (F6) had increased BACH1 levels (Figure 15). GAPDH served as a loading
control. It is still apparent that more BACH1 was detected in the F6 subline expressing
the least amount of miR-155. Thus, miR-155 expression is affecting the level of protein
expression from both transfected sensor constructs as well as endogenous protein levels.

miR-155 expression alters the morphological structures of F6 cells
Previously, it was determined that the M12 and F6 sublines display distinct
differences in morphology when cultured embedded in Matrigel (3D) that correlates with
their differences in tumorigenic/metastatic behavior in vivo (X. Zhang, unpublished
observations). To determine if miR-155 expression has an affect on the morphology of
the F6 cell line, light microscope analysis of F6+ph1pa-155, M12, and F6 structures were
conducted after twelve days of growth embedded in Matrigel. Visual observations
showed that F6 cells formed balls-of-cells, without projections or obvious spreading
throughout the Matrigel (Figure 16). The M12 subline showed large collections of cells
with obvious cellular extensions between clusters (see arrows), which correlates with
their enhanced growth and movement throughout Matrigel. F6+ph1pa-155 showed large
balls-of-cells like F6, but with extensions between cells like M12 (see arrows). Thus, the
addition of miR-155 does alter the morphology of the F6 cell line.
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Figure 15. BACH1 expression is repressed in cell lines with high levels of miR-155.
(A) Preliminary western blot evaluating BACH1 levels in P69, F6, M12, F6+ph1pa-155,
and F6+ph1pa. (B) Western blot evaluating BACH1 protein levels in F6, M12, and
F6+ph1pa-155. Western blot analyses of whole cell protein extracts (60µg) analyzed via
4-20% SDS polyacrylamide gel electrophoresis. BACH1 was diluted 1:500 and GAPDH
is included as a loading control (1:10,000 dilution).
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Figure 16. Expression of miR-155 in F6 alters morphology in 3D. Light microscope
pictures of F6, M12, and F6+ph1pa-155 after 12 days of growth embedded (3D) in
Matrigel. F6 shows many individual ball-of-cells without extensions to other cellular
groups. M12 shows distinct projections away from the central accumulation of cells to
neighboring groups of cells (see arrows in M12). F6 cells with miR-155 over expression
show many individual ball-of-cells like F6, but also show extensions between groups of
cells (see arrows in F6+ph1pa-155).
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Immunoflourescent staining investigates the morphology of F6+ph1pa-155
A Z-stack shows sequential images through an F6+ph1pa-155 structure. The
nuclei (blue) showed cells were located throughout the ball-of-cells without evidence of a
true lumen, reflecting what is defined as a spheroid (Figure 17A-L). In addition, there is
an extension between the two individual spheroids (note arrows in Figure 17J), which
may represent the ability of the cells to reach out and move, like M12. Interestingly, the
spheroid in the right upper corner of the Z-stack images showed a small inner mass of
cells in the center of the spheroid. Acini formation is thought to occur through apoptosis
of such inner masses of cells, resulting in a hollow lumen. It appears that this spheroid
might be attempting such a process, but incompletely. This was an interesting, but
isolated observation.
Further evaluation of 3D morphological structures in F6+ph1pa-155 cells
following growth embedded in Matrigel was needed to establish internal structure and
potential polarity of cellular adhesion proteins. F6+ph1pa-155 structures were stained
with antibodies to vimentin, β-catenin, and α6-, β1- and β4-integrins (Figure 18A-D.).
Figure 18A showed F6 structures exhibiting some polarity with definite co-localization of
α6- and β4-integrins at the plasma membrane as confirmed on the merged image. M12s
showed co-localization, but no polarity of the integrin pair, whereas F6+ph1pa-155
showed co-localization and intermediate polarity of both integrins. Figure 18B showed
similar results as Figure 18A. Figure 18C depicts β-catenin staining, which is basolateral
in F6 structures, but associated with the membrane outlining each cell in the cluster of
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Figure 17. F6+ph1pa-155 form solid spheroids without a lumen. An image at every
third plane from a Z-stack of F6+ph1pa-155 shows the nuclei (blue) forming two solid
spheroids, with cells extending between then (arrows in panel j.). In panels d-i.the upper
right spheroid shows a layer of cells surrounding a center cluster of cells, but no true
lumen is present. Panels g-l., show the lower left spheroid completely void of lumen. A
measurement of 5µm is on the lower right of each panel.
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Figure 18A. Expression of miR-155 in F6 altered morphological structures. α6integrin (green), β4-integrin (red), and merged are stained as indicated. A measurement
of 5µm is on the lower right of each panel.
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Figure 18B. Expression of miR-155 in F6 altered morphological structures. α6integrin (green), β1-integrin (red), and merged image are stained as indicated. A
measurement of 5µm is on the lower right of each panel.
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Figure 18C. Expression of miR-155 in F6 altered morphological structures. βcatenin (red) is stained as indicated. A measurement of 5µm is on the lower right of each
panel.

Figure 18D. Expression of miR-155 in F6 altered morphological structures.
Immunoflourescent staining comparing the morphological structures between F6, M12,
and F6+miR155. (D)Vimentin (green) is stained as indicated. A measurement of 5µm is
on the lower right of each panel.
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M12 and F6+ph1pa-155 cells. Finally, Figure 18D depicts the staining of vimentin,
which is absent in F6 structures and present in both M12 and F6+ph1pa-155 structures.

miR-155 affects the morphological size of F6 structures grown in 3D
A comparison between P69, F6, and F6+ph1pa-155 was performed to evaluate the
affect of miR-155 on the size of spheroid growth. Zhang et al. (unpublished results)
determined the acini diameter of P69 and F6 structures grown in 3D from day 3 through
15. The diameter of the solid spheroids formed by the F6+ph1pa-155 cell line grown in
3D was compared to the positive slope of P69 and F6 at two stages of growth, day 6 and
day 12 (Figure 19). At day 6, the diameter of the F6+ph1pa-155 spheroid was double
that of P69 and F6 acini, 61µm compared to 32 µm and 30 µm, respectively. At day 12,
the F6+ph1pa-155 spheroids were just under double the diameter of P69 and F6 acini,
111µm compared to 64µm and 60µm, respectively. The diameter of M12 structures was
undeterminable because these M12 do not form acini or even a solid sphere of cells when
grown in 3D (see Figure 17).

Mature miR-146a mRNA levels are up regulated in metastatic M12
The initial microarray screen suggested miR-146a might be a potential oncomiR
when comparing the two prostate cancer cell lines, M12 to F6. To determine the
endogenous levels of mature miR-146a, a specific Taqman qRT-PCR was performed on
P69, M12, and F6 (Figure 20). It was found that miR-146a had a 9.9-fold higher
expression level in M12 compared to P69 and a 7.0-fold higher expression between M12
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Figure 19. miR-155 increases the diameter of F6 cells. The diameter of P69 and F6
acini was quantitated and compared to the diameter of F6+ph1pa-155 spheroids at day 6
and 12 when grown in Matrigel (3D).
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Figure 20. mir-146a is up regulated in metastatic M12 cell line. The endogenous
expression of the mature form of miR-146a is up regulated in M12 compared to P69 and
F6. Four samples of each cell line was evaluated in triplicates, and normalized to an
internal control, RNU48. Each bar represents the standard error. Italicized values
represent fold-difference compared to P69; bold values represent fold-difference
compared to F6.
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and F6. These observations confirm data from the initial microarray screen, but at a
lower fold difference.

Over expression of miR-146a in F6 cells
To determine the affect of miR-146a over expression on F6 cell behavior, the
precursor sequence was cloned into pSiren-RetroQ vector and F6 stably transformed cells
were constructed as described in Materials and Methods. In addition, a non-targeting
sequence was also inserted into the vector, serving as a control (pSiren-NTC).
Determining the mature miR-146a level in stably transfected F6 cells was performed
using specific Taqman primers and qRT-PCR. F6+pSiren-146a had a 195-fold higher
expression compared to F6, a 272-fold higher expression compared to P69, and a 28-fold
higher expression compared to M12. F6+pSiren-NTC had no increase in mature miR146a levels (Figure 21).
To evaluate the affect of the microenvironment on the expression of mature miR146a levels, M12, F6, and F6+pSiren-146a cells were grown embedded in Matrigel and
assayed using the specific Taqman qRT-PCR (Figure 22). Comparison of miR-146a in
M12 and F6+pSiren-146a 3D showed a 353-fold and 911-fold higher expression
compared to F6, and a 2.6-fold higher expression in F6+pSiren-146 compared to M12.
Although the extracellular environment enhanced the miR-146a level in M12 3D
compared to 2D (2.4-fold increase), a decrease in F6 3D compared to 2D (21-fold
decrease) and a decrease in F6+pSiren-146a 3D compared to 2D (4.5-fold decrease) was
also seen. Thus, the microenvironment of Matrigel is exerting an effect on specific miR
expression.
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Figure 21. miR-146a is over expressed in the stably transformed F6+pSiren-146a
cell line. Following the stable transfection of miR-146a into F6, mature miR-146a levels
were evaluated using specific Taqman qRT-PCR. Four samples from each cell line were
evaluated in triplicate and normalized to the internal control, RNU48. Bars represent the
standard error. Italicized values represent fold-difference compared to P69; bold values
represent fold-difference compared to F6.
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Figure 22. miR-146a is up regulated in M12 and F6+pSiren-146a grown in 3D.
miR-146a is up regulated in M12 and F6+miR-146a when grown embedded in Matrigel,
compared to F6. Two samples from each cell line were evaluated in triplicate, and
normalized to an internal control, RNU48. Each bar represents the standard error. Bold
values represent fold-difference compared to F6.
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miR-146a affects the growth of F6 cells
The affect of miR-146a on the growth of M12, F6, F6+pSiren-146a, and
F6+pSiren-NTC cells was monitored over twelve days using the WST-1 proliferation
reagent. The positive slopes derived by linear trendline showed M12 and F6+pSiren146a cells proliferated at the same rate, 0.529 and 0.563, respectively. Likewise, F6 and
F6+pSiren-NTC proliferated at similar rates, 0.268 and 0.275, respectively. Based on the
positive slopes, M12 and F6+pSiren-146a had increased proliferation rates compared to
F6 and F6+pSiren-NTC (Figure 23).

miR-146a affects the motility and invasiveness of F6 cells
A dual chamber system was used to determine the affect of miR-146a on motility
and invasion of F6 cells. M12, F6, F6+pSiren-146a, and F6+pSiren-NTC cells were
plated in the upper chamber of a Transwell insert in serum starved media, with
chemoattractant media placed in the lower chamber. M12 was 3.6-times more motile
than F6 (113.8 cells per field compared to 31.7 cells) and F6+pSiren-146a 2.7-times more
motile than F6 (86.7 cells per field compared to 31.7 cells), but F6+pSiren-146a was only
0.75-times as motile as M12 (Figure 24A). Thus, the over expression of miR-146a is
having some effect on the motility of F6 cells. The invasiveness of cells was evaluated
using the same dual chamber system, but with cells placed on top of a Matrigel coated
Transwell insert, as mentioned in Methods and Materials. M12 cells were the most
invasive, with 155.6 cells per field, a 389-fold difference compared to F6 cells (0.4 cells
per field). F6+pSiren-146a was also invasive, but not to the extent of M12, with only

84

Cell Line
M12
F6+pSiren-146a
F6
F6+pSiren-NTC

Linear Trendline
Y= 0.529x - 0.775
Y= 0.563x - 1.021
Y= 0.268x - 0.437
Y= 0.275x - 0.479

Figure 23. miR-146a affects the cell proliferation of F6. The proliferation of M12,
F6, F6+pSiren-146a, and F6+pSiren-NTC cells was observed over twelve days by
measuring the WST-1 absorbance at 450nm. Each cell line had eight samples read per
assay and was normalized to wells without cells (blank). Bars represent the standard
error.
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Figure 24. miR-146a affects the motility and invasiveness of F6. (A) F6, M12,
F6+pSiren-146a, and F6+pSiren-NTC cells were plated in the upper chamber of a
Transwell insert, subjected to chemoattractants in the lower chamber, and then allowed to
migrate for 48h. Migrated cells were fixed, stained, and counted in 5 random fields per
filter (thirty in total) at 400X magnification. Bars represents the standard error. (B) F6,
M12, F6+pSiren-146a, and F6+pSiren-NTC were plated on Matrigel-coated Transwell
inserts, subjected to chemoattractants in the lower chamber, and then allowed to migrate
for 48h. Migrated cells were fixed, stained, and counted in 5 random fields per filter
(thirty in total) at 400X magnification. Bars represent the standard error. Bold values
represent fold-difference compared to F6.
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103.1 cells per field, a 257-fold difference compared to F6 cells. The control vector,
F6+pSiren-NTC was comparable to F6 with 0.9 cells per field compared to 0.4 cells per
field, respectively (Figure 24B). In the presence of Matrigel, the highly motile cells
(M12 and F6+pSiren-146a) became more invasive, and the less motile cells became
nearly non-invasive.

miR-146a elicits an effect on TRAF6
To demonstrate that miR-146a affects the protein level of a target mRNA, a
luciferase sensor construct was evaluated. TRAF6 3’-UTR was proposed to be a
miR-146a target via a screen of the miR sequence target databases (TargetScan, PicTar,
Miranda) and confirmed experimentally (19). M12 had a slightly lower luciferase
activity value, 35, compared to F6, 38. F6+pSiren-146a over expressing 146a drove
down TRAF6 luciferase activity level to 27 (Figure 25). Although the relative TRAF6
luciferase level was not down regulated to a significant level in M12, the over expression
of miR-146a in F6 (having 27.6 times more miR-146a than M12) did decrease TRAF6
and concurs that TRAF6 is a target for miR-146a.

Immunoflourescent staining depicts the morphological structure of F6+pSiren-146a
grown in 3D
In order to evaluate the affect of miR-146a on the internal composition of the F6
subline, a Z-stack was performed on an F6+pSiren-146a ball-of-cells structure grown in
3D. Sequential images of every third plane were obtained, showing the nuclei (blue) of
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Figure 25. miR-146a affects TRAF6. TRAF6 3’UTR was transiently transfected into
F6, M12, and F6+pSiren-146a cells and luciferase activity measured as described in
Material and Methods. Reporter gene firefly activity was normalized to internal renilla,
serving as an internal control. Results are the average of one set of triplicates and bars
represent the standard error. Bold values represent fold-difference compared to F6.
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cells located throughout the entire structure, with no evidence of a lumen (Figure 26).
This reflects a solid spheroid structure. Therefore, miR-146a does affect the
morphological structure of the F6 cell line when grown in 3D.

miR-146a affects the morphological size of F6 structures when grown in 3D
To evaluate the affect of miR-146a on F6 cells, P69, F6, and F6+pSiren-146a
structures were compared when cells were grown in 3D. Zhang et al. (unpublished data)
previously determined the diameter of P69 and F6 structures grown in 3D from day 3
through 15. The diameter of F6+pSiren-146a structures grown in 3D was compared to
the positive slope of the plotted acini diameters of P69 and F6 at two stages of growth,
day 6 and day 12. At day 6 F6+pSiren-146a had a diameter of 20.7µm, 0.33 times
smaller than P69 and F6. Visual observations of F6-pSiren-146a cells showed little
structure formation at day 6. At day 12, F6+pSiren-146a cells were well structured with
a diameter of 123.8µm, 2 times higher than P69 and F6 (Figure 27). Thus, miR-146a
expression does increase the diameter of F6 structures grown in 3D.
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Figure 26. F6+pSiren-146a form solid spheroids without a lumen. A-J. Show an
image at every third plane from a Z-stack of F6+pSiren-146a. The staining of α6-integrin
(green) and the nuclei (blue) show formation of a solid spheroid without a lumen. A
measurement of 5µm is on the lower right of each panel.
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Figure 27. miR-146a increases the diameter of structures formed by the F6 subline
grown in 3D. Following growth in 3D, the diameter of P69 and F6 acini were
quantitated and compared to the diameter of F6+pSiren-146a spheroids at day 6 and 12.
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DISCUSSION
microRNAs are found to be both up regulated and down regulated in cancer. A
microarray analysis found two potential up regulated oncomiRs in a prostate cancer
progression model. qRT-PCR further confirmed that miR-155 and miR-146a were
indeed up regulated in the metastatic M12 cell line compared to its non-metastatic and
barely tumorigenic variant, F6. The affect miR-155 and miR-146a had on prostate cancer
cells was evaluated through stable over expression into the F6 cell line and compared to
M12. It was shown that over expression of both miRs does increase cell growth, motility,
invasiveness, and affects cellular morphology.
The qRT-PCR measurements of miR-155 expression in the stably transfected F6
subline grown in 2D indicate that miR-155 is expressed at levels comparable to M12.
The miR-155 levels in 3D showed an up regulation of miR-155 in F6, M12, and
F6+ph1pa-155 above those levels found in 2D; however, when grown embedded in
Matrigel the F6+ph1pa-155 cell line expressed miR-155 at one-half the level exhibited by
the M12 cell line. This result suggests the presence of extracellular matrix is controlling
miR gene expression. Since Matrigel mimics the host’s extracellular environment, the F6
versus M12 miR-155 levels detected in 3D might be a more accurate representation of the
level of miR gene expression in human prostate cancer cells. In other words, the
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microenvironment may be influencing the F6+ph1pa-155 cells to down regulate miR-155
expression in attempts to maintain their non-metastatic “F6” behavior. The morphology
of the cellular structures grown in 3D supports this hypothesis. The morphology of
F6+ph1pa-155 is intermediate to the characteristics displayed by the highly metastatic
M12 subline versus the weakly tumorigenic, non-metastatic F6 subline. Unpublished
data from Zhang et al. showed F6 structures having an organized and polarized acini
structure with a definite lumen. F6+ph1pa-155 cells also show an organized collection of
cells, but they do not exhibit a lumen. Instead they form a solid spheroid of cells. They
also have display an intermediate polarization of integrins, much like F6, but with
cellular extensions between spheroids, like the M12 cells. In addition, the positive
staining of vimentin in F6+ph1pa-155 and M12 cell lines, but none in the F6 subline,
further indicates that the F6+ph1pa-155 subline is showing some tumorigenic
characteristics of the M12 subline. Vimentin is a known marker for mesenchymal cells
and depicts cells that have transgressed through an epithelial-mesenchymal transition,
EMT (15). Moreover, in most cancers like breast, vimentin expression is indicative of
poorly differentiated, highly metastatic tumor cells with poor prognosis (50).
Interestingly, here vimentin is expressed by both the metastatic M12 and F6+ph1pa-155
sublines, but not the parental F6 or F6+ph1pa sublines suggesting the progression of
these cells to a more tumorigenic/metastatic state by the restoration of miR155
expression. How miR-155 expression might be regulating vimentin expression is
presently unknown.
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MicroRNAs target the 3’UTR of mRNA through perfect or imperfect matching
and down regulate their expression by either degradation or translational repression,
respectively. Evaluation of three miR-155 targets, BACH1, c-Fos, and c-maf, confirmed
that they were targets of miR-155. All three targets showed relatively high luciferase
activity in F6 and F6+ph1pa, but were down regulated in M12 and F6+ph1pa-155
sublines. These results agree with the paradigm that high miR levels cause translational
repression of a target mRNA and low miR levels permit protein expression. More
importantly the ph1pa vector is not having an effect on these targets, but rather the effect
is due to expression of the particular miR. BACH1 appears to be the best target for miR155 because the over expressing F6 cell line resulted in BACH1 levels reduced to a
physiological comparable level to that exhibited by the M12 subline. The vector only F6
cell line had levels comparable to F6. BACH1 is a helicase involved in double stranded
DNA repair, and its down regulation in the M12 cell line could allow for the
accumulation of DNA breaks and mutations, pushing these cells towards a more
tumorigenic behavior. Thus, BACH1 could be a major player in the tumor progression of
the M12 cell line.
In addition, c-Fos and c-maf sensor constructs both showed decreased expression
in M12 compared to F6, with intermediate down regulated expressions in F6+ph1pa-155.
Like in BACH1, the empty vector and F6 had comparable levels. The repression of cmaf might also contribute to oncogenesis. Recently it has been shown that the c-maf
transcription factor induces the expression of the tumor suppressor p53 (44). The p69,
M12 and F6 cell lines are known to contain wild-type p53 (personnel communication,
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Joy Ware). Thus, an increase in miR-155 would cause a decrease in c-maf, leading to
decreased levels of the p53 tumor suppressor, allowing cells to push towards unmitigated
growth and oncogenesis. It is unclear at this stage why decreased levels of c-Fos would
be beneficial to the metastatic M12 cell line. c-Fos is a well known and described protooncogene that has been experimentally confirmed to have high mRNA expression levels
in prostate cancer compared to BPH (51). Therefore, M12 having high miR-155 levels
would target the proto-oncogene and decrease c-Fos expression, as confirmed in Figure
14C. A decrease in the proto-oncogene would theoretically mean oncogenesis would be
halted. c-Fos is not only a proto-oncogene, but is one of many transcription factors that
dimerize with Jun family members, allowing for gene expression (51). However, Western
blot analysis showed that none of these cell lines, p69, M12, F6, F6+ph1pa-155 or F6
plus vector only, are normally expressing measurable amounts of c-fos protein. It is
assumed that the addition of a stress modulater such as phorbol ester (TPA) would induce
c-fos expression in these cell lines and this induction would be eliminated by over
expression of miR-155 in the F6+ph1pa cells as has been shown in other cell lines and
supported here by c-fos luciferase sensor construct activity (52). In these cell lines, c-fos
is not being expressed and thus normally would not be playing a role in tumor
progression under these conditions.
The evaluation of miR-155 targets in the over expressing F6 cell line (F6+ph1pa155) show BACH1 to be the most repressed target out of the three putative targets
analyzed here. As mentioned in the introduction, the function of miRs to repress
translation is directly correlated to the match between the 5’seed sequence of the mature
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miR to its mRNA 3’UTR target. Presumably, a complete match between the mRNA seed
sequence, nucleotides 2-8 (5’ to 3’ on the mature miR), is required to target a miR to a
particular message. However, additional matches between the miR and its target would
aid in both the selection and stability of this interaction. As shown in Figure 5A, the
BACH1 3’UTR has two functional binding sites for miR-155 at seed position nucleotide
2-8. The c-Fos 3’UTR (Figure 5B) shows only one binding site (at seed nucleotides 2-6
and 8) for miR-155 targeting. Figure 5C shows three regions on the c-maf 3’UTR that
miR-155 could target. miR-155 matches to the seed region of the three c-maf 3’UTR
sequences at nucleotides 2-7, 2-6 and 8, and 2-7. Simply comparing the matches in the
seed region between miR-155 and the target mRNA does not reveal an answer as to why
BACH1 is more repressed in F6+ph1pa-155, compared to c-Fos and c-maf. An
examination of the sequence match between the 3’-region of miR-155 and the 5’-region
of c-Fos and c-maf, (i.e., base matches outside the seed sequence recognition region)
reveals little matching even when invoking base pair wobble. Conversely, the 3’-region
of miR-155 and the 5’-region of BACH1 show at least five base matches, which
represent canonical miRNA:mRNA interaction as previously mentioned in the
introduction. Canonical interaction, one of the three proposed base-pairing mechanisms
miRs use for recognition of a target mRNA, is the binding interaction of the 5’- and 3’end of the miRNA. Thus, BACH1 may potentially represent stronger binding, by having
two specific and important binding sites, which exhibit a more favorable negative energy
of binding between the miR and its target mRNA.
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Investigation of BACH1 protein levels independent of a reporter system was
analyzed via a Western blot. Multiple blots were performed at different protein
concentrations and antibody dilutions. Previous blots not depicted showed protein
loading to be unequal. The band densities of GAPDH were evaluated using BioRad
Quantity One 4.4.0 application and normalized to each other in order to correct for the
unequal protein load. The antibody provided by Zymed produced many contaminating
bands, one of which fell very close to the GAPDH loading control band, and the densities
were skewed based on this contaminating band. Therefore, when the Western blot was
performed the nitrocellulose membrane was cut at the 50kDa band, allowing for
independent antibody incubations and thus avoiding the contaminating band depleting the
levels of BACH 1 antibody. Unfortunately, determining that the contaminating band was
in fact skewing the loading control band was not observed until after the Western blot
depicted in Figure 15A was performed. The blot in Figure 15A does show protein
loading disparities, but it is important to include for it shows a large amount of BACH1
protein in F6 compared to M12, with a much lower GAPDH protein concentration in F6
compared to M12. In addition, the vector only cell line showed BACH1 present. It is
inconclusive at this time to determine if miR-155 in the F6+ph1pa-155 cell line is having
the same affect on BACH1 as M12 due to the protein loading error. An additional
western blot was performed, Figure 15B, and depicts high levels of BACH1 in F6 with
decreased levels in M12 and F6+ph1pa-155, much like the original blot but with equal
protein loading.
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Similar to the miR-155 results, miR-146a was shown to be up regulated in the
metastatic M12 cell line compared to barely tumorigenic and non-metastatic F6 subline in
the initial microarray screen. Confirmation of the differential expression was evaluated
through qRT-PCR in P69, F6 and M12 cell lines, confirming that miR-146a was up
regulated in M12 compared to P69 and F6. The potential role of miR-146a in tumor
progression was evaluated through the over expression of miR-146a in the F6 subline.
qRT-PCR results confirmed that miR-146a was being over expressed in the stable
transformant, but at much higher and incomparable levels compared to M12. However,
the F6 plus vector only was at levels comparable to F6 without vector, indicating that the
vector alone was not exhibiting an effect on miR-146a expression. Further evaluation of
miR-146a in F6, M12, and F6+pSiren-146a 3D samples was performed using specific
Taqman qRT-PCR. It was shown that miR-146a expression was suppressed in F6 cells at
a level 21 times lower than the 2D results. miR-146a expression was up regulated in
M12 3D compared to 2D, noting a 15-fold increase. Lastly, miR-146a expression was
down regulated in F6+pSiren-146a 3D compared to 2D, noting a 4.5-fold decrease. The
decrease in miR expression in F6 and F6+pSiren-146 in 2D compared to 3D, again marks
the importance of the extracellular environment and the role it may play in influencing
gene expression. Since F6 cells are barely tumorigenic and non-metastatic, the
microenvironment of the extracellular matrix is influencing the cells to behave like barely
tumorigenic and non-metastatic cells, thus decreasing the effect of a putative oncomiR.
In addition, the decrease in miR-146a expression in F6+pSiren-146a might mark the
microenvironment trying to influence the “F6” part of the cell transformant to remain
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non-metastatic and barely tumorigenic. Nonetheless, miR-146a in M12 and F6+pSiren146a was expressed in 3D at much higher levels compared to F6.
The morphological changes miR-146a may potentiate in the F6 cell line was
evaluated by immunoflourescent staining. A Z-stack of multiple images of a F6+pSiren146a structure showed the structure to be a solid spheroid of cells with the absence of a
lumen, much like the F6+ph1pa-155 structures. There were no cellular projections
between spheroids as noted in F6+ph1pa-155. The analysis of vimentin, β-catenin, and
α6-, β1-, and β4-integrins was inconclusive due to poor antibody staining.
miR-146a did have an affect on the TRAF6 sensor construct, but not to levels that
would represent TRAF6 as being a major player in tumor progression. As noted in
Figure 25, the expression of miR-146a in the M12 cell line did not down regulate TRAF6
sensor construct activity to a significant fold difference. But, the over expression of miR146a in the F6 transformant did indeed drive down the TRAF6 activity below that of
M12, thus confirming TRAF6 as a miR-146a target. Additionally, the target sequence of
miR-146a in the 3’UTR of TRAF6 mRNA (Figure 6), had extensive homology in the
seed regions, matching to nucleotides 2-7, even further supporting TRAF6 as a target of
miR-146a. The mild reduction of TRAF6 expression in M12 and F6+pSiren-146a may
be explained by the fact that TRAF6 is an important player in immunity and immune
cells, and the expression of TRAF6 in the prostate cancer progression model is not as
important as its expression in other cell lines. Thus, TRAF6 might show differential
expression between various tissues but in the prostate gland it does not represent an
adequate source for experimental analyses.
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miR-155 and miR-146 both had effects on the growth of F6 cell lines. The cell
proliferation of F6 transformants compared to M12, F6, and F6 with vector only, showed
a marked increase in proliferation to levels equal and above those of M12. The spheroid
diameter of F6+pSiren-146a 3D structures was determined after 6 and 12 days of growth
and compared to the previously determined acini diameters of P69 and F6. The diameter
size at day 12 reflects a much large cell mass and corresponds with the proliferation assay
showing F6+pSiren-146a’s positive slope approximately twice as great as F6 or F6 with
vector only. Likewise, the diameter of F6+ph1pa-155 3D structures at day 6 and 12
compared to the cell proliferation assay. At day 6 and 12, F6+ph1pa-155 had double the
WST-1 absorbency, which corresponds to the spheroid diameter being double that of F6
and P69. These results are in line with the suggestion that an increase in proliferation
rate results in an increase in cell number, necessitating an increase in cell mass (diameter)
of structures formed in 3D.
miR-155 did show an effect on the motility and invasiveness of the F6 cells lines.
M12 and F6+ph1pa-155 were shown to have similar motility and invasive properties
(Figure 12). Although F6 and F6+ph1pa also had similar motility and invasive properties
to each other, they were considerably much lower than M12 and F6+ph1pa-155. More
importantly the vector had no effect. The average number of M12 and F6+ph1pa-155
cells able to move through the Matrigel layer was higher than the motility of cells
cultured in the absence of Matrigel layer (1.4-fold increase). The average number of F6
and F6+ph1pa cells able to move through the Matrigel were considerably reduced in the
absence of Matrigel layer (80-fold reduction). Likewise, miR-146a showed an effect on
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motility and invasiveness in the F6 cells, but to a lesser extent compared to miR-155.
M12 and F6+pSiren-146 were 3- and 4-fold more motile compared to F6 and F6+pSirenNTC, respectively. M12 and F6+pSiren-146a were 389- and 113-fold more invasive
compared to F6 and F6+pSiren-NTC. Like in the case of cells over expressing miR-155,
cells over expressing miR-146a (M12 and F6+pSiren-146a) have an increase in
invasiveness compared to motile cells when placed on Matrigel. In addition, F6 and
F6+pSiren-NTC markedly decrease their motility in the presence of Matrigel, going from
31.7 and 16.6 motile cells, respectively, in the presence of the filter only to 0.4 and 0.9
cells, respectively, in the presence Matrigel on the filter. This marks a 79-fold decrease
in cellular movement in F6 cells subjected to the microenvironment of extracellular
matrices and an 18-fold decrease in F6+pSiren-NTC. These comparisons between
motility and invasiveness for both miR-155 and miR-146a show that the
microenvironment might act as a chemoattractant for motile cells and amplify their
metastatic and invasive behaviors, whereas blocking invasiveness of less motile cells.
This finding is in agreement with the results Ware et al. found, that M12 cells were
metastatic and F6 cells were non-metastatic (14, 15). An invasive behavior in vitro might
correspond to a metastatic behavior in vivo. In summary, miR-155 and miR-146a
exhibited an effect on putative targets, increased cellular growth, motility, and
invasiveness, and lastly altered the morphology of structures to those which represent
more metastatic structures. Thus, miR-155 and miR-146a could potentially play an
important role in prostate tumor progression and the metastatic nature of M12 cells,
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which now warrants further testing by subcutaneous and orthotopic injection into the
prostate of male, athymic mice.
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